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ABSTRACT 
Over the course of the viral life cycle many host cell factors act to either restrict or facilitate viral 
infection.  Identification of these factors gives insight into the cell biology and virology of viral 
infection, perhaps even leading to identification of therapeutic targets.  A highly efficient and un-
biased method for identifying these factors is high-throughput RNAi screening.  Our lab previously 
conducted such a screen in search of host cell factors that regulate enterovirus infection, and this 
dissertation describes characterization of two screen ‘hits’: Gp78, whose depletion restricted 
enterovirus infection, and BPIFB3, whose depletion enhanced enterovirus infection.  In aim 1 we 
show that the E3 ubiquitin ligase Gp78 is a regulator of the retinoic acid-inducible gene 1 (RIG-
I)-like receptor (RLR) antiviral signaling pathway. We show that depletion of Gp78 results in 
enhancement of type I interferon (IFN) signaling, restricting RNA virus infection.  
Mechanistically, we show that Gp78 modulates type I IFN induction by altering both the 
expression and signaling of the mitochondria-localized RLR adaptor mitochondrial antiviral 
signaling (MAVS). Our data implicate two parallel pathways by which Gp78 regulates MAVS 
signaling—one pathway requires its E3 ubiquitin ligase activity to directly degrade MAVS, 
whereas the other pathway occurs independently of these activities, but requires association 
between the Gp78 RING domain and MAVS.  In aim 2, we characterize the role of bactericidal 
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permeability-increasing protein (BPI) fold-containing family B member 3 (BPIFB3), a member of 
the lipid-binding antimicrobial BPI/lipopolysaccharide (LPS) binding protein (LBP) family of 
proteins, in viral infection.  We show that BPIFB3 is ER-localized, and examination of ER 
morphology upon BPIFB3 depletion shows that it is involved in maintenance of ER architecture.  
We further show that ER-regulated calcium homeostasis is also disrupted in the absence of 
BPIFB3.  Examination of the role of BPIFB3 in viral infection led to the finding that depletion of 
BPIFB3 enhances VSV-induced syncytia formation.  The increase in syncytia could be correlated 
with an observed increase in endosome/lysosome number and size, although concrete evidence to 
support this connection is lacking at this time.  Lastly, we show that BPIFB3 plays a role in 
infection of a diverse panel of viruses, all of which require host-derived membranes for their life 
cycles.  Taken together, our data show that BPIFB3 is a novel component of the ER that is 
responsible for maintenance of ER morphology, and that depletion of BPIFB3 affects replication 
of viruses that utilize host-derived ER membranes or trafficking for their life cycles.  This project 
is significant to public health because it furthers understanding of virus-host cell interaction, which 
is crucial for development of efficient and targeted anti-viral therapeutics.       
 
 
 v 
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1.0  INTRODUCTION 
There are many critical interactions between a virus and host cell during the course of viral 
infection.  These interactions include those that restrict and those that facilitate completion of the 
viral life cycle, and identification of host cell factors involved provides valuable information on 
the cell biology and virology of viral infection.  To identify novel host cell factors involved in 
enterovirus infection our lab previously performed a high-throughput RNAi screen for novel 
regulators of enterovirus infection, identifying Gp78 and BPIFB3 as potential regulators of 
infection.  In this dissertation introduction, various aspects of virus-host cell interaction, as well as 
host cell components known to be hijacked for the viral life cycle, are discussed with a particular 
focus on host cell components involved in the life cycle of positive-sense RNA viruses.  The screen 
“hits” chosen for follow-up in this dissertation (Gp78 and BPIFB3) are also discussed. 
 
1.1 HOST-VIRUS INTERACTION 
1.1.1 Positive-sense RNA virus life cycle 
The nucleic acid contained within a virus can take one of seven different forms, including RNA or 
DNA, single (ss) or double-stranded (ds), and a positive or negative polarity in the case of ssRNA 
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viruses.  The ssRNA virus group contains the most members, and among the ssRNA viruses, the 
positive sense RNA viruses are the most numerous (1).  The following section outlines the general 
life cycle of positive sense RNA viruses, and includes the steps of viral entry, genome release, 
genome translation and replication, virus assembly, maturation, and egress.     
Positive sense RNA viruses have small genomes encoding a limited number of proteins, 
thus they rely on many host cell factors throughout their life cycle.  A schematic of the general life 
cycle of positive-sense RNA viruses is shown in Figure 1 (2).   Viral attachment and entry involves 
the engagement of host cell surface molecules with viral surface proteins, resulting in direct fusion 
and uncoating at the membrane of some enveloped viruses, or receptor-mediated endocytosis of 
non-enveloped and some enveloped viruses (1).       
Following entry, the positive sense RNA contained within the viral capsid is released into 
the cytoplasm of the host cell.   Like viral entry, genome release requires a set of host cell endocytic 
trafficking proteins.  Genome release is commonly accomplished through fusion of the incoming 
virus-containing endocytic vesicle with lower pH-containing early/late endosomes, thus triggering 
pH-dependent conformational changes in viral proteins to allow genome escape by either 
membrane fusion (enveloped viruses) or disruption of the endosomal membrane (non-enveloped 
viruses) (3).  From early endosomes to late endosomes/lysosomes the pH of the compartment 
lowers progressively to a pH of 5.0 (4).  Therefore, the stage of post-entry endocytic trafficking 
from which a particular viral genome escapes its vesicle depends on its individual pH requirement. 
Once the RNA has reached the cytoplasm direct translation of the positive sense genome 
occurs.  This step relies almost exclusively on the host cell translation machinery since the polarity 
of viral positive-sense RNA mimics the mRNA of the host cell.  RNA viruses whose genome lacks 
the usual 5’ terminal cap and 3’ poly-A tail of host cell mRNA utilize a variety of different 
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strategies to hijack the host cell translation machinery, including utilization of an internal ribosome 
entry site (IRES) in the 5’ untranslated region of the RNA for recruitment of the ribosome (5-8).  
Whereas host cell mRNA molecules are monocistronic (meaning they encode for only one 
functional protein each) most viral RNA molecules are polycistronic.  This allows for more 
efficient protein production from a limited genome.  An example of this is illustrated by the 
picornaviruses.  Translation of the picornaviral RNA is initiated by ribosome binding at the IRES, 
resulting in the translation of a polyprotein containing all viral proteins.  The polyprotein is then 
cleaved into individual functional proteins by two viral proteases (7, 9, 10).     
Once the production of viral proteins has begun, replication of the viral RNA can 
commence.  This is because the host cell does not normally produce RNA from an RNA template, 
and therefore the host cell does not contain the correct polymerase to achieve this (an RNA-
dependent RNA polymerase, or RDRP).  Thus, viral RNA replication cannot begin until the RDRP 
has been translated.  There are host cell proteins involved in the active replication of positive-sense 
RNA viruses.  For example poliovirus (PV) requires the host protein poly (rC) binding protein for 
initiation of replication (11, 12).  However, many of the host cell factors required for positive-
sense RNA virus replication are the membranes and lipids that provide the scaffolding and 
protection for the viral replication complex (13), and this will be addressed in further detail in 
section 1.1.2.   
The last steps in the viral life cycle include assembly of the progeny virions followed by 
their maturation and release.  During assembly of the progeny virions the viral structural proteins 
are assembled into a viral capsid structure and the newly replicated viral RNA packaged inside it 
to produce new virions, which often takes place at or near host cell-derived membranes.  In some 
cases, the newly assembled virion must undergo a maturation process prior to becoming a fully 
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infectious viral particle.  An example of this is illustrated by PV.  Cleavage of structural protein 
VP0 into VP2 and VP4 is required for a fully mature and infectious PV particle to be released (14).  
In other cases the acquisition of a viral envelope from the host cell membranes constitutes part of 
the maturation process.  Viral egress is a diverse process among positive-sense RNA viruses, and 
includes the cytopathic event of host cell lysis to allow release of viral particles (as for most non-
enveloped viruses such as poliovirus), viral hijacking of the host exocytic pathway, or budding 
from the membrane in the case of viruses that assemble at the plasma membrane.  During all of 
these different exit strategies the virus relies heavily on host cell factors to achieve release of the 
mature infectious virus particle (1).        
 
 
 
 
Figure 1. Positive-Sense RNA virus life cycle. 
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A general schematic of the positive-sense RNA virus life cycle, including attachment and entry, RNA release into the 
host cell cytoplasm, translation of viral RNA to produce structural proteins and those required for replication complex 
assembly, viral assembly, and finally maturation and release.  From Stapleford et al., 2010 (full reference in text). 
 
 
1.1.2 Positive-sense RNA virus replication and host membranes 
Host cell membranes and lipids are recognized as vital to the replication of many RNA viruses, 
including picornaviruses and flaviviruses. Viruses have diverse mechanisms and intracellular 
sources for construction of viral replication centers from the host membranes.  Picornavirus 
replication, including PV and coxsackievirus B (CVB), was shown to induce an extensive 
reorganization of ER, Golgi and lysosome membranes into membrane-bound vesicles, providing 
a scaffold on which to organize replication machinery and for protection from innate immune 
recognition (15-18).   CVB begins replication on the Golgi and trans-Golgi membranes where it 
remains until newly synthesized viral proteins assemble on viral replication complexes formed 
near ER exit sites (19).  The viral proteins 3A and 3CD are involved in inhibition of secretory 
system trafficking and reorganization of the membranes into viral replication centers (19, 20), 
which are enriched in many factors of the host secretory system, including the GTPase ADP-
ribosylation factor 1 (ARF1) and its guanine exchange factor (GEF) GBF1 (19).  ARF1 seems to 
be involved in recruiting factors to ensure the appropriate membrane curvature and lipid content 
for viral replication (20, 21).  Viral replication centers are also enriched in the Golgi protein PI4Kβ, 
which participates in synthesis of phosphoinositide membrane lipids.  Higher levels of these 
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membrane lipids, in turn, recruit the PV RDRP to viral replication centers and provide the 
appropriate lipid microenvironment for PV replication (19). 
The flavivirus hepatitis C virus (HCV) was shown to form a similar ER membrane-derived 
viral replication center referred to as the membranous web (22).  It contains ER-derived 
membranes organized into a web of vesicles in close proximity to lipid droplets.  Interestingly, 
HCV seems to have the same requirement of enriched phosphoinositide membrane lipids as PV 
for replication and therefore recruits a similar yet distinct ER-localized PI4K (PI4Kα) via the viral 
protein NS5A for this purpose (22-25). 
Viral exploitation of host-derived membranes to facilitate replication has now been shown 
to be a requirement of all positive sense RNA viruses (26-28). These sites of replication exist in 
close proximity to sites of viral translation and assembly, allowing coordination of these closely 
linked processes (29). In fact, PV assembly requires actively replicating RNA, raising the notion 
that the membranous replication centers are important for steps in the viral life cycle beyond 
replication (30).   
Regulation of the lipid content of host-derived membranes for viral replication seems to be 
a common theme among positive-sense RNA viruses.  The viral requirement of membranes for 
replication explains the early observation that PV, like many other RNA viruses, modulates lipid 
biosynthesis (31). The flavivirus Dengue virus was also shown to affect lipids by modulating 
expression and distribution of the essential lipid synthesis molecule fatty acid synthase (FASN) to 
promote formation of its replication complexes (32).  This is achieved by the viral protein NS3, 
which recruits FASN to the ER membrane where DENV replication centers are located and 
increases its activity in order to increase local availability of fatty acids.  This in turn results in 
further formation of viral replication centers. 
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1.1.3 Innate Immunity 
RNA viruses produce RNA species during their replication cycle that are recognized by the host 
cell as “foreign”, which is crucial for containment of RNA virus infection by the host innate 
immune response.  As such, recognition of pathogen-derived nucleic acids is among the most 
important of the host cell’s defense against invading pathogens and represents another example of 
how host-pathogen interaction affects the outcome of disease.  Endosome-localized toll like 
receptors (TLRs) and the cytosolic sensors of the RLR pathway are the major sensors of viral RNA 
(Fig 2).  
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Figure 2. Innate Immune Signaling. 
Incoming viral RNA is recognized by either the endosomal TLRs or the cytosolic RLRs.  Type I interferon signaling 
then ensues to create an antiviral state.  Schematic courtesy of Dr. Carolyn Coyne. 
 
 
The endosome-localized TLRs known to recognize viral RNA are TLR3, TLR7, and TLR8. 
Although it remains unclear where exactly viral RNA sensing takes place, some evidence suggests 
 8 
that in some cell types they may sense viral RNA directly following receptor-mediated endocytosis 
of viruses that utilize this entry pathway or through the fusing of infection-induced 
autophagasomes with the TLR-containing endosomes (33-40). TLR7 and TLR8 recognize ssRNA 
(37-39) and TLR3 recognizes dsRNA, including replication intermediates and by-products from a 
range of viruses with different nucleic acid compositions (35, 36, 40-42). Upon recognition of their 
respective ligands, the aforementioned TLRs initiate a signaling cascade resulting in the 
production of type I interferon and/or pro-inflammatory cytokines. TLR3 signals through TRIF 
and TRAF3, ultimately resulting in phosphorylation and nuclear translocation of IRF3 to activate 
transcription of IFN-β (43-46). TLR7 and TLR8 signal through MyD88 and TRAF6 ultimately 
resulting in the degradation of IκB and nuclear translocation of NF-κB to activate transcription of 
pro-inflammatory cytokines and/or the phosphorylation and nuclear translocation of IRF7 to 
activate transcription of IFN-α (47, 48).  
Although there exists a certain degree of redundancy in terms of pathogen recognition and 
type I interferon/pro-inflammatory cytokine induction between endosomal TLRs and the RLR 
pathway, there are also important differences. Whereas the endosome-localized TLRs sense viral 
nucleic acids from within an endosome, the RLR pathway consists of cytosolic RNA sensors for 
recognition of actively replicating RNA viruses, which takes place only in the cytosol. Since some 
RNA viruses avoid exposure to the endosome, either due to the nature of their life cycle or 
strategies to evade innate immunity, this redundancy ensures recognition. It is important to note 
however, that like the endosomal TLRs, the exact location of RNA recognition by cytosolic RLRs 
remains unclear, and could include locations that are not strictly cytosolic.  The cytosolic sensors 
of the RLR pathway also exist in a broader range of cell types than the endosomal TLRs, enabling 
many cell types to protect themselves and neighboring cells from viral infection.  
 9 
The RLR pathway begins with recognition of distinct species of viral-derived RNA by one 
of the two cytosolic sensors retinoic acid inducible gene-I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA5). The first identified sensor of the RLR pathway was RIG-I, consisting 
of two N-terminal caspase recruitment domains (CARDs) that were sufficient to induce 
downstream signaling, a central DEAD box helicase/ATPase domain and a C-terminal regulatory 
domain necessary to prevent constitutive activation (49). The model holds that once RNA is bound 
an ATP-dependent conformational change takes place allowing the N-terminal CARD domains to 
interact with the downstream adaptors, an interaction that is facilitated by ubiquitination of RIG-I 
by the E3 ubiquitin ligase TRIM25 (50, 51). It recognizes RNA with uncapped 5’-ppp generated 
by viral polymerases and RNA containing short dsRNA structure motifs and/or poly-uridine motifs 
that mark RNA as non-self (49, 52-56). These ligands represent genetic material produced during 
replication of a variety of different positive and negative strand RNA viruses including some 
flaviviruses and orthomyxoviruses (57-59). The less characterized cytosolic sensor is MDA5, 
which structurally resembles RIG-I in that it contains two N-terminal CARD domains and a central 
DEAD box helicase/ATPase domain but lacks the C-terminal regulatory domain (60). MDA5 does 
not recognize uncapped 5’ppp RNA, and is thought to bind to activated long stable dsRNA 
structures such as RNA replication intermediates that might be hybridized to genome RNA during 
infection (61). Importantly, it is thought to be the main sensor responsible for recognition and 
response to picornavirus infection (62). There are also some groups of viruses that are recognized 
by both RIG-I and MDA5, including some flaviviruses, paramyxoviruses and reoviruses (57-59). 
The discrepancies and similarities between virus groups recognized by each sensor have been key 
in discovering their respective ligands, since each viral life cycle gives clues to the RNA species 
produced.  
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Although RIG-I and MDA5 differ in the cytoplasmic ligands they sense, they signal 
through a common mitochondria-localized adaptor (mitochondrial antiviral signaling, MAVS, also 
known as IPS-I, CARDIF, VISA) through interactions with their CARD domains. MAVS also 
contains an N-terminal CARD domain that mediates the interaction and the downstream signaling 
event, as well as a C-terminal transmembrane domain localizing it to the mitochondrial membrane. 
This localization is required for downstream signaling events as well (63-66). Beyond MAVS, 
many of the downstream signaling molecules overlap with those of the endosomal TLRs.  MAVS-
mediated antiviral signaling is propagated through assembly of a MAVS ‘signalosome’ including 
TRAF3, TRAF6, TRAF family member-associated NF-κB activator (TANK) and TANK binding 
kinase 1 (TBK1). The formation of a MAVS signaling complex results in the phosphorylation and 
nuclear translocation of interferon regulatory factor (IRF)-3 by TANK binding kinase 1 (TBK1) 
and/or IKKε, as well as activation of nuclear factor kappa beta (NF-κB) to induce type I interferons 
(IFNs) and pro-inflammatory cytokines (43, 45, 67, 68). 
1.2 MAVS REGULOME 
 
Because enhanced levels of inflammation can elicit cell damage and/or insufficient levels of 
inflammation can inhibit the ability of cells to remove the invading threat, mechanisms must be in 
place to tightly regulate antiviral signaling. Regulation at the mitochondrial level is quite strategic 
given that signals propagated by independent cytosolic sensors converge on MAVS at the 
mitochondrial membrane. Therefore, regulators of MAVS exert a higher level of control than they 
might if they targeted upstream components of RLR signaling such as RIG-I or MDA5 
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individually. In the following sections are detailed the variety of mechanisms by which regulators 
specifically modulate MAVS expression and/or signaling, with a focus on those that regulate by 
(1) protein-protein interactions, (2) alterations in mitochondrial dynamics, and/or (3) post-
translational modifications (Figure 3 and Table 1, note:  not all regulators presented in Figure 3 
and Table 1 are discussed in the text). 
 
 
Figure 3. Mechanisms of MAVS regulation. 
There are multiple mechanisms by which MAVS is regulated to exert cellular control over innate immune signaling.  
MAVS can be regulated by host cell factors that inhibit MAVS signaling by direct protein-protein interactions, by 
altering mitochondrial properties or dynamics, or by post-translational modifications.  PRR, Proline-rich region; Ub, 
Ubiquitination; P, Phosphorylation.  Positive regulators of MAVS signaling are shown in green text and negative 
regulators of MAVS signaling are shown in red text. Note that LGP2 is shown in both red and green given conflicting 
results on its role in the regulation of RLR signaling. 
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Table 1. The MAVS Regulome categorized by mechanism of regulation.   
Ub, Ubiquitination; P, Phosphorylation; (+), positive regulation; (-), negative regulation 
 
Protein-Protein 
Interactions 
Mitochondrial Dynamics 
Post-translational 
Modifications (Ub or P) 
LGP2 (+/-) (60, 69-
74) 
Fusion (+)/Fission(-) (75, 
76) 
PSMA7 (-) (Ub) 
(77) 
NLRX1 (-) (78-82) MFN1 (+) (75, 83) 
PCBP2/AIP4 (-) 
(Ub) (84) 
MFN1 (+) (75, 83) MFN2 (+) (75, 76, 85) 
TRIM25 (+) (Ub) 
(86) 
MFN2 (-) (87) ↑∆Ψm (+)  (76) 
Ndifp1/Smurf1 (-) 
(Ub) (88) 
TOM70/HSP90 (+) 
(89) 
MAM (+) (75, 85) 
TSPAN6 (-) (Ub) 
(90) 
IFIT3 (+) (91) FAK (+) (92) PLK1 (-) (P)* (93) 
gC1qR (-) (94) COX5B/ATG5 (-) (95) C-Abl (+) (P) (96) 
UBXN1 (-) (97)   
*PLK1 does not directly phosphorylate MAVS, but rather may require phosphorylation of MAVS for docking of PLK1 at an 
upstream site prior to PLK1 binding near the C terminus of MAVS where it exerts regulatory activity. 
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1.2.1 Regulation of MAVS by protein-protein interactions 
In addition to RIG-I and MDA5, a third RNA helicase harboring a DExD/H box RNA helicase 
domain exists and is termed LGP2 (laboratory of genetics and physiology gene 2). LGP2 exhibits 
30-40% amino acid sequence identity to RIG-I and MDA5 and is capable of dsRNA binding (60, 
69). However, and quite importantly, LGP2 lacks a CARD with which to signal to downstream 
mediators of IFN induction, which has suggested a different function for LGP2 than for either 
RIG-I or MDA5. Consistent with a possible role in innate immune function, the expression of 
LGP2 is induced by type I IFNs, dsRNA, and virus infection (60, 69). However, unlike RIG-I and 
MDA5, overexpression of LGP2 results in a downregulation of IFN-β promoter activity (60, 69). 
Indeed, LGP2 has been suggested to serve as a negative regulator of the RLR pathway via its 
interaction with MAVS at the mitochondrial membrane, thus preventing its vital association with 
the downstream signaling molecule TRAF3 (70). A later study reported that MAVS 
homooligomerization of its N-terminal CARD domain, dependent on the C-terminal mitochondrial 
localization domain, resulted in more efficient signaling (73). This suggests that while LGP2 
association with MAVS might prevent its association with TRAF3, it could also interfere with 
MAVS dimerization.  
In addition to the negative regulation of MAVS, LPG2 has also been suggested to directly 
regulate RLRs themselves. LGP2-/- MEFS are more susceptible to synthetic RNA (poly (I:C)) 
stimulation of IFN production and LGP2-/- mice are less sensitive to lethal vesicular stomatitis 
virus (VSV) infection, a rhabdovirus known to signal through RIG-I (presumably due to enhanced 
IFN production and subsequent infection control). However, these results were not observed with 
encephalomyocarditis virus (EMCV), a picornavirus known to signal through MDA5 (74). These 
seemingly disparate results suggest that RIG-I may actually serve as the target of LGP2-mediated 
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downregulation of IFN production (71). A later study showed that LGP2 was actually a positive 
regulator of RLR signaling, facilitating RNA sensing by RIGI-I and MDA5, and was essential for 
the response of MDA5 to picornaviruses (72). Thus, the role of LGP2 in innate immunity remains 
somewhat unclear and more work is needed to determine at which step(s) of the RLR pathway 
LGP2 exerts its effect. 
Mitochondrially-localized proteins represent logical candidates for the regulation of 
MAVS. The first mitochondrial protein that was identified as a negative regulator of MAVS was 
the nucleotide-binding domain (NBD)- and leucine-rich-repeat (LRR)-containing family member, 
NLRX1 (98). NLRXs are members of the NOD-like receptor family of cytosolic pattern 
recognition receptors (PRRs) that are involved in innate immunity independent of RLR signaling. 
This study successfully confirmed the putative localization of NLRX1 to the outer mitochondrial 
membrane, and went on to show that it interacted with MAVS via its CARD, disrupting vital 
MAVS interactions with upstream signaling partners (98). These data were corroborated in 
NLRX1-/- MEFs. IFN-β production was increased in NLRX1-/- MEFs infected with a variety of 
viruses known to engage RIG-I. However, there was no change in response to EMCV, a virus 
known to engage MDA5 (78). Interestingly, cells deficient in NLRX1 exhibited RIG-I/MAVS 
association even in the absence of infection whereas the MDA5/MAVS association was only 
present after viral infection (78). The constitutive association between RIG-I and MAVS in the 
absence of NLRX1 could account for the increase in IFN-β in response to infection with RIG-I-
engaging viruses but not MDA5 engaging viruses. Conflicting results do exist, however, as 
subsequent studies in two independently-derived NLRX1-/- MEFs found no potentiation of IFN 
induction or IRF3 phosphorylation in response to poly (I:C) stimulation or Sendai virus (SeV) 
infection compared to WT MEFs, and no change in the serum level of IFN-β in NLRX1-/- mice 
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compared to WT mice upon injection with poly (I:C) (81, 82). Another study reported NLRX1-
mediated inhibition of RLR signaling to be an artifact of inhibition of luciferase activity, which is 
quite relevant since many of the previous studies used luciferase-based assays to measure RLR 
signaling (79). Like LGP2 inhibition of MAVS activity, NLRX1 inhibition of MAVS activity has 
yielded conflicting results. It is certainly possible that NLRX1 has multiple regulatory roles, 
depending on whether positive or negative regulation is advantageous for the cell but more studies 
are needed to reconcile disparate findings and elucidate the role of NLRX1 in MAVS signaling.   
The mitofusins (MFN1 and MFN2) are residential outer mitochondrial membrane proteins 
that play roles in regulating mitochondrial dynamics by controlling fusion, and MFN2 has been 
reported to act as a mitochondria-ER tethering protein (99, 100). While screening the MAVS 
mitochondrial supramolecular complex by mass spectrometry for MAVS interacting partners, 
MFN2 was identified as an interacting partner of MAVS (87). Upon further investigation, 
overexpression of MFN2, but not MFN1, was found to inhibit RIG-I-, MDA5-, and MAVS-
mediated type I IFN induction. Conversely, RNAi–mediated silencing of MFN2 as well as studies 
in MFN2-/- MEFs showed that RLR signaling was enhanced in knockdown cells, a phenotype that 
was reversed upon addition of exogenous MFN2 into these cells. These results were corroborated 
in a later study (76). Immunoprecipitation studies confirmed that MAVS and MFN2 interact and 
that this interaction was dependent upon the mitochondrial localization of MAVS and occurred 
between a central hydrophobic heptad repeat (HR1) region of MFN2 and a C terminal region of 
MAVS (87). 
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1.2.2 Regulation of MAVS by mitochondrial dynamics 
Utilizing protein-protein interactions as a means of regulating of MAVS-mediated innate immune 
signaling is clearly important. However, the physical properties of the mitochondria and the 
resulting changes in MAVS distribution and/or aggregation can also play an important role in its 
regulation. Initial evidence for the role of mitochondrial dynamics in MAVS signaling came from 
studies demonstrating that infection of cells with Sendai virus or transfection of poly (I:C) resulted 
in elongation and/or fusion of mitochondria, leading the authors to conclude that activation of RLR 
signaling results in physical alterations in the mitochondria themselves (75). Indeed, this study 
also showed that phosphorylation of IRF3 was delayed in cells with fragmented mitochondria and 
that RLR signaling was attenuated by mitochondrial fragmentation, but enhanced upon 
mitochondrial fusion. Immunoprecipitation experiments showed that MAVS forms an interaction 
with mitofusin 1 (MFN1), a protein that regulates mitochondrial fusion events, suggesting a 
possible role for this interaction in the regulation of the mitochondrial dynamics that accompany 
antiviral signaling. Interestingly, a later study also reported on the interaction of MFN1 with 
MAVS and further showed that MFN1 acts as a positive regulator of MAVS-mediated antiviral 
signaling by redistributing MAVS to speckle-like aggregates observed upon activation of RLR 
signaling (83). This could explain why MFN1 and mitochondrial fusion seem to be important for 
RLR signaling given that fusion of the mitochondria could facilitate MAVS aggregation. Others 
further investigated the role of MFNs in MAVS signaling using MEFs deficient in both MFN1 and 
MFN2 (MFNs-dm) (76). These cells were unable to undergo mitochondrial fusion, and were 
impaired in their ability to produce IFN-β and IL-6 in response to viral infection. In light of the 
results of these studies, it is likely that the role of MFNs in innate immune signaling is multifold. 
Not only do both MFN1 and MFN2 interact directly with MAVS to exert a regulatory role, but 
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their activities in mitochondrial dynamics also appear to be important for MAVS functioning. This 
is in accordance with earlier reports that MAVS activation requires self-association into higher 
order oligomers (73) as well as formation of large prion-like aggregates for potent propagation of 
antiviral signaling (101). Other studies have also pointed to a direct role for another mitochondrial 
process in RLR signaling as carbonyl cyanide m-chlorophenylhydrazone (CCCP), a compound 
known to dissipate mitochondrial membrane potential (∆Ψm), resulted in suppressed innate 
immune signaling (76), thus suggesting that ∆Ψm is another example of a mitochondrial process 
that is important for regulation of MAVS-mediated signaling. Taken together, these reports 
suggest that mitochondrial elongation and fusion may facilitate the aggregation of MAVS into 
active complexes primed for maximum signaling capacity. 
In addition to regulating mitochondrial fusion, MFN2 is also important in the tethering of 
the mitochondria to the ER at the mitochondria-associated membrane (MAM). The MAM is 
emerging as an important subcellular domain in MAVS signaling. For example, virally-infected 
cells exhibit increased numbers of ER contacts with elongated mitochondria compared to 
uninfected control cells, suggesting that ER-mitochondria contacts increase upon infection-
induced mitochondrial fusion and elongation (75). This of particular significance given that the 
population of MAVS residing at the MAM is important for antiviral signaling (85).  
Regulation of reactive oxygen species (ROS) production has also been reported to play a 
role in the regulation of RLR signaling from the mitochondria (102-105). While examining the 
mechanism for this phenomenon, Zhao et al. described cytochrome C oxidase (COX) 5B as a 
MAVS interacting partner responsible for repression of ROS- and RLR-signaling (95).  COX5B 
is a mitochondrial protein and is a member of the cytochrome c oxidase complex (CcO), the 
complex that catalyzes the last step in the electron transport chain (106). Overexpression of 
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COX5B decreased MAVS-mediated antiviral signaling without having any effect on TLR-
mediated or TNF-α-induced signals, suggesting the effect was specific to the RLR pathway (95). 
Cells depleted of COX5B also exhibited enhanced antiviral signaling. Interestingly, in addition to 
its role in ATP production, COX5B has been shown to be involved in the negative regulation of 
ROS production (107). To investigate the possible role of this pathway in COX5B-mediated 
regulation of MAVS, the authors utilized two compounds reported to alter ROS levels and found 
that an increase in ROS resulted in an increase in MAVS-mediated signaling and decreasing ROS 
levels resulted in a decrease of MAVS-mediated signaling. In addition, cells expressing exogenous 
MAVS produced higher levels of ROS, which was abrogated by exogenous COX5B (95). 
Interestingly, COX5B expression was not induced by addition of purified IFN-β, but was induced 
in the presence of overexpressed MAVS, suggesting that it is not an interferon-inducible gene but 
its expression is coordinated with MAVS expression for its specific negative regulation.   
MAVS overexpression induces autophagy (or perhaps, more specifically, mitophagy) (95) 
and ROS production has also been associated with the induction of autophagy (108). Because 
autophagy is involved in the removal of aggregated proteins (109, 110) and the aggregation of 
MAVS during RLR activation is known to potentiate signaling (73, 83, 101), COX5B and 
regulators of autophagy such as ATG5 might regulate MAVS-mediated signaling by affecting 
MAVS aggregation upon its activation. Indeed, MAVS aggregation is affected by the expression 
of ATG5 and COX5B, with overexpression leading to decreased aggregation and depletion leading 
to increased aggregation (95). These results suggest that COX5B works coordinately with ATG5 
to negatively regulate MAVS-mediated antiviral signaling through an increased clearance of 
MAVS aggregates in addition to its role in repression of ROS production.  
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1.2.3 Regulation of MAVS by post-translational modification 
The post-translational control of proteins is a common means by which cells regulate diverse 
pathways and processes. It is thus not surprising that post-translational modifications of MAVS 
and/or its interacting partners are a key aspect of host cell regulation of antiviral signaling. A yeast 
two-hybrid screen for MAVS interacting partners identified the proteasomal component PSMA7 
as a MAVS interacting partner (77). PSMA7 is a subunit comprising the outer ring of the 20S 
catalytic core complex of the 26S proteasome and is involved in proteasomal activity regulation 
(111, 112). MAVS interaction with PSMA7 requires both the C-terminal transmembrane domain 
and the CARD region of MAVS (77). Overexpression of PSMA7 reduced IFN-β induction and 
suppressed VSV infection whereas its silencing yielded the opposite results. Consistent with these 
findings, overexpression or depletion of PSMA7 decreased or increased endogenous MAVS 
protein levels, respectively (77). Importantly, MAVS mRNA levels remained unchanged in 
response to these manipulations, suggesting that PSMA7 modulated MAVS levels post-
transcriptionally. Indeed, PSMA7 overexpression induced the ubiquitination of MAVS, 
implicating the PSMA7-mediated proteasomal degradation of MAVS. However, given that 
PSMA7 protein has not been shown to be involved in the process of protein ubiquitination itself, 
it is clearly not the only player in this process. Thus, it remains to be seen if PSMA7 recruits 
enzymes of the ubiquitination pathway for MAVS ubiquitination prior to recruiting ubiquitinated 
MAVS to the proteasome for degradation. 
The multi-protein requirement for ubiquitin-mediated degradation and negative regulation 
of MAVS is emerging as a common theme in the regulation of RLR signaling. After performing a 
yeast two-hybrid screen in search of interacting partners of MAVS, poly(rC) binding protein 2  
(PCBP2) was identified as a negative regulator of MAVS (84). PCBP2 is involved in RNA and 
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DNA binding with many different purposes in the cell, including mRNA stability and translation 
regulation (113). Overexpression of PCBP2 resulted in suppression of MAVS-mediated IFN-β 
induction, but had no effect on TBK1- or IRF3-induced signaling. PCBP2 expression was highly 
inducible by interferon treatment and virus infection, and the interaction between endogenous 
PCBP2 and endogenous MAVS was inducible by Sendai virus infection. Subcellular localization 
studies showed that endogenous PCBP2 localized primarily to the nucleus, but relocalized to the 
cytoplasm where it colocalized with MAVS upon viral infection or MAVS overexpression. 
Despite lacking any ubiquitin ligase activity itself, PCBP2 overexpression induced a dramatic 
proteasome-dependent degradation of MAVS. Using mutational analysis of MAVS, the authors 
showed that ubiquitination of two specific lysine residues led to its degradation, and that the levels 
of MAVS polyubiquitination were higher in the presence of overexpressed PCBP2. Given that 
PCBP2 is not an enzyme of the ubiquitination pathway, the authors hypothesized that PCBP2 could 
be acting as physical scaffold linking MAVS to an E3 ubiquitin ligase. Screening known E3 
ubiquitin ligases for a candidate that both mediates degradation of MAVS and binds to PCBP2, 
the authors found the Nedd4-like E3 ubiquitin ligase AIP4. Overexpression of AIP4 partially 
abrogated IFN-β signaling and induced MAVS degradation in a manner dependent on its E3 
ubiquitin ligase activity. Although AIP4 and MAVS were shown to interact, this interaction 
required PCBP2, suggesting that PCBP2 acts as a scaffold to facilitate AIP4-mediated degradation 
of MAVS. This was confirmed using in vitro ubiquitination assays which showed that PCBP2 
expression greatly increased the AIP4-mediated ubiquitination and degradation of MAVS. Finally, 
type I IFN signaling was enhanced in Itch (the mouse homologue of AIP4)-/- MEFs further linking 
this E3 ligase to MAVS signaling. Collectively, this study nicely showed that PCBP2 acts as an 
adaptor for AIP4-mediated ubiquitination and subsequent proteasomal degradation of MAVS for 
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negative regulation of RLR signaling, elucidating a quite novel and interesting mechanism of RLR 
regulation. A later report by the same group showed that PCBP1, a protein highly similar to PCPB2 
(114, 115), is also involved in negative regulation of MAVS-mediated signaling using a similar 
mechanism (116). However, unlike PCBP2, PCBP1 is not induced by type I IFNs, leading the 
authors to conclude that it is a “housekeeper” of MAVS levels rather than a negative feedback 
inhibitor.     
Ndfip1 has also been classified as a negative regulator of MAVS at the mitochondria 
through enhancement of ubiquitination and proteasomal degradation (88). In light of mounting 
evidence linking E3 ubiquitin ligase activity to MAVS regulation, Ndifp1 is a logical candidate 
given its reported role in enhancement of protein ubiquitination through interaction with a family 
of E3 ubiquitin ligases known as Nedd4 ubiquitin ligases, particularly in signaling pathways (117, 
118). MAVS-mediated signaling was inhibited by Ndfip1 in a proteasome dependent manner. As 
these results pointed to ubiquitination-mediated proteasomal degradation as the mechanism of 
negative regulation of MAVS by Ndifp1, the authors next screened the four known members of 
the Nedd4 E3 ubiquitin ligase family for their ability to induce MAVS degradation in the presence 
of Ndifp1. The Nedd4 E3 ubiquitin ligase Smurf1 was shown to lead to degradation of MAVS, 
but not of RIG-I or TBK1, in the presence of Ndifp1. The interaction between Smurf1 and MAVS 
was increased in the presence of Ndifp1, as was the Smurf1-mediated ubiquitination of MAVS, 
indicating that Ndifp1 likely serves as an adaptor for recruitment of Smurf1 to MAVS. This study 
described a mechanism of MAVS negative regulation that is quite similar to that of PCBP2 and 
AIP4 as discussed above, and provides yet another example of the complexity of ubiquitination in 
the regulation of MAVS signaling. 
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Adding a different twist to the recently emerging and growing role of ubiquitination in 
RLR signaling, tetraspanin protein 6 (TSPAN6) was recently described to play a role in MAVS-
mediated RLR signaling (90). TSPAN6 is a member of the membrane-embedded tetraspanin 
protein family that has been shown to have many different functions in the cell, including various 
roles in host immunity (119). Interestingly, TSPAN6 does not promote the ubiquitination of 
MAVS either directly or indirectly, but is itself ubiquitinated in order to promote its association 
with MAVS and disrupt the mitochondrial-localized signalosome. Overexpression of TSPAN6 
resulted in a reduction of exogenous MAVS-induced signaling and was shown to interact with 
MAVS. TSPAN6 is ubiquitinated in response to RLR activation, which is involved in its 
association with MAVS. The authors propose that ubiquitination of TSPAN6 in the presence of 
viral infection promotes its recruitment to the mitochondria where it interacts with MAVS, 
abrogating the assembly of the signalosome and thus inhibiting antiviral signaling. The enzyme(s) 
responsible for ubiquitination of TSPAN6 in the context of RLR activation remains to be 
discovered. 
Like ubiquitination, phosphorylation represents a post-translational mechanism of protein 
regulation in many cellular processes. Yeast two-hybrid screening identified the Polo-like kinase 
1 (PLK1) as an interacting partner for MAVS (93). PLK1 is a serine/threonine Polo-like kinase 
(120-122). Contrary to other known regulators of MAVS, induction of antiviral signaling did not 
enhance the association between MAVS and PLK1. PLK1 interacts with MAVS at two unique 
regions, downstream of the CARD region and just upstream of the C terminus (the interaction 
downstream of the CARD region is dependent upon phosphorylation of MAVS at position Thr234) 
(93). The phosphorylation-independent C-terminal interaction was shown to be responsible for the 
attenuation of IFN signaling due to a disruption of MAVS-TRAF3 interaction. This finding has 
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been corroborated by more recent work that has uncovered a second TRAF3 binding site in MAVS 
corresponding to this same region (123). Work is ongoing to determine the specific kinase(s) 
responsible for the primary phosphorylation of MAVS that facilitates PLK1 binding.   
  More recently, the tyrosine kinase c-Abl was identified as a MAVS-interacting partner 
that acts as a positive regulator of MAVS by direct interaction and phosphorylation (96). c-Abl is 
a nuclear and cytoplasmic Src-like non-receptor protein tyrosine kinase that is known to serve 
many cellular functions (124). The interaction between MAVS and c-Abl was shown to require 
both the transmembrane domain and CARD of MAVS, likely suggesting that mitochondrial 
localization of MAVS is required for this interaction. Depletion of c-Abl resulted in abrogation of 
MAVS signaling and pharmacological inhibition of c-Abl abrogated IFN-β production in response 
to VSV infection. The tyrosine phosphorylation of MAVS was enhanced by c-Abl expression, but 
not by a c-Abl mutant defective in kinase activity. In a later report, tyrosine-scanning mutational 
analysis revealed that inducible phosphorylation at Tyr9 of MAVS was involved in the recruitment 
of TRAF3/TRAF6 to propagate MAVS-mediated RLR signaling (125). Whether c-Abl is involved 
in phosphorylation of Tyr9 of MAVS remains to be determined, and would represent an interesting 
follow-up to these two studies. 
In conclusion, antiviral signaling is an extremely powerful cellular response that 
necessitates tight regulation in order to adequately neutralize invading threats while avoiding 
damage to the cell from excessive inflammation.  A large portion of antiviral signaling regulation 
has evolved at the mitochondria due to its pivotal position in the antiviral signaling pathway.  
Strategically, this is a logical step for regulation because of the convergence of independent 
upstream sensors on the common mitochondrial signaling adaptor protein MAVS.  As discussed 
above, the cell employs many diverse mechanisms to regulate MAVS, including protein-protein 
 24 
interactions for physical blockage of MAVS association with upstream or downstream signaling 
partners, alterations of mitochondrial physical dynamics as well as the physical 
distribution/aggregation of MAVS, and post-translational modifications such as phosphorylation 
and ubiquitination. Although remarkable progress has been made, there is still much to be learned 
regarding the myriad of mechanisms by which host cells regulate MAVS-mediated signaling.  
Ongoing work in the field will continue to identify MAVS regulators, hopefully providing a 
complete picture of the MAVS regulome. 
1.3 GP78/AMFR 
Autocrine motility factor receptor (AMFR, gp78) was discovered as a cell surface receptor for 
the cytokine autocrine motility factor (AMF), the activity of which has been linked with 
increased cancer metastasis presumably due to its role in cell differentiation, survival and 
growth. The presence of AMF and AMFR has been correlated with poor cancer prognosis and 
tumor cell motility (126-131). Sequence analysis later pointed to a putative role as an E3 
ubiquitin ligase due to the presence of a RING domain and a Cue domain (132), and it has now 
been extensively characterized as a five transmembrane ER-localized E3 ubiquitin ligase of the 
ER-associated degradation (ERAD) pathway.  The ERAD pathway recognizes misfolded 
proteins in the ER, marking them for proteasomal degradation by the process of ubiquitination 
(133).  The process of ubiquitination relies on three classes of enzymes: E1, E2 and E3.  E1s are 
the ubiquitin activating enzymes, which bond to the ubiquitin molecule via a thiol ester bond, 
passing the activated ubiquitin to the E2s.  The E2s are the ubiquitin conjugating enzymes, and 
the E3s are the ligases responsible for transfer and ligation of the ubiquitin from the E2s to the 
 25 
substrate.  Addition of ubiquitin molecules to the substrate is repeated until a polyubiquitin chain 
is formed and the substrate is degraded (134).  The E3 ubiquitin ligase activity of Gp78 requires 
a C-terminal RING domain (responsible for ubiquitin ligase activity), Cue domain (responsible 
for ubiquitin binding), and E2 binding site (135-137). The C-terminus also contains a site of 
interaction with the AAA ATPase p97 (VCP), which provides the driving force for translocation 
of the polyubiquitinated substrates to the cytosol for subsequent degradation by the proteasome 
(Figure 4) (138-141).  Known substrates of Gp78 include the mutant cystic fibrosis 
transmembrane regulator (CFTR∆508) (142), HMGCoA reductase (a key enzyme in the 
cholesterol synthesis pathway), which is degraded in a regulatory manner in response to high 
cholesterol levels (143), apolipoprotein B (the protein component of low and very low density 
lipoprotein), which is also degraded in a regulatory manner (144), and KAI1 (CD82), which is a 
tetraspanin metastasis suppressor (145).  In localization studies it was found both in the plasma 
membrane in caveolae, consistent with its role as a cell surface receptor, and, importantly, at the 
peripheral smooth ER in close association with mitochondria (146-150).  The Gp78-specific 
antibody 3F3A was shown early on to label smooth ER tubules distinct from the rough ER, 
representing a distinct subpopulation of Gp78 (147, 149).  These 3F3A-labeled tubules were 
shown to exhibit direct calcium-dependent interactions with mitochondria, thus Gp78 can be 
described as MAM-localized (148, 150).  Interestingly, this interaction may have consequences 
for the mitochondria since exogenous Gp78 was recently shown to induce proteasomal 
degradation of the mitofusin proteins MFN1 and MFN2 resulting in mitochondrial 
fragmentation.  Gp78 was further shown to induce mitophagy upon depolarization of the 
mitochondrial membrane (151).        
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Figure 4. Topology of Gp78. 
Gp78 is an ER-localized membrane-bound E3 ubiquitin ligase of the ERAD pathway, requiring its ring finger (RF), 
Cue, and E2 binding region (G2BR) for its ligase activity.  Schematic courtesy of Dr. Carolyn Coyne. 
1.4 ER MORPHOLOGY 
The endoplasmic reticulum (ER) is a large cellular organelle that is involved in production of 
membrane-bound and secreted proteins, lipids, maintaining calcium homeostasis, and protein 
quality control.  It consists of an extensive and dynamic continuous membrane-bound system 
throughout the interior of the cell that is contiguous with the nuclear membrane and stretches into 
the periphery of the cell.  The ER membrane system can be divided into two distinct morphological 
categories.  The nuclear envelope and perinuclear region of the ER is formed from sheet-like 
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cisternal structures, in which flat membranes are arranged closely spaced to one another. The 
peripheral ER is comprised of tubules of ~50 nm diameter (152-155).  These distinct domains 
appear to have distinct functions as well.  The ER sheets that make up the perinuclear ER consist 
mostly of “rough” ER, meaning the sheets are studded with ribosomes.  Therefore, this region of 
the ER is involved in production of secreted and membrane proteins.  The tubular peripheral ER 
is comprised of mostly smooth ER (lacking ribosomes) and is involved in functions other than 
protein production, such as lipid synthesis, calcium homeostasis, contact with other cellular 
organelles (such as endosomes and mitochondria) and lipid droplet formation (156-160).  The 
proportion of rough perinuclear ER sheets to tubular, smooth peripheral ER is often dependent on 
the function of the cell type, as well as the cellular growth stage and external conditions.  For 
example, professional secretory cells contain a higher amount of rough ER sheets than smooth ER 
tubules due to the necessity for high levels of protein production, whereas a hepatic cell contains 
a higher amount of smooth ER tubules because of an increased need for carbohydrate metabolism 
(154).    
An important feature of ER membranes that accounts for morphologic differences between 
regions is the degree of membrane curvature.  The diameter of ER tubules as well as the luminal 
thickness of ER sheets are ~50 nm, but the difference in their shapes lies in the degree of membrane 
curvature.  ER tubules have a much higher degree of membrane curvature than sheets, which are 
curved only at the ends of longer leafs (161).  Interestingly, the sites of ER-to-Golgi secretory 
pathway initiation, termed ER exit sites (where COP-II-coated vesicles bud bearing newly 
synthesized proteins headed for the Golgi apparatus), have been shown in highly curved tubular 
regions of the ER such as the tubular regions and the ends of ER sheets, possibly due to the ease 
of vesicle budding from a highly curved membrane surface (162).   
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Generating and maintaining ER curvature is accomplished by a number of proteins.  The 
high curvature in ER tubules is achieved by the reticulon and DP1/Yop1p families of proteins, and 
this is reflected by their enrichment in tubular regions of the ER as well as the curved edges of ER 
sheets (163, 164).  Both families of proteins are proposed to work by inserting into the ER 
membrane outer leaflet using two transmembrane domains, therefore causing a wedge in the 
membrane and forcing membrane curvature (163, 165).  
Although the previously mentioned proteins are required for the membrane curvature 
required at the ends of ER sheets, an independent set of proteins is responsible for the formation 
of the flat apposed membranes characteristic of the interior of ER sheets.  These proteins were 
implicated in formation of ER sheets when identified via a screen for proteins enriched in the 
sheet-containing domain of the ER, and they include Climp63, p180, and kinectin (164).  All three 
of these proteins contain coiled-coil domains that function in the formation and stabilization of ER 
sheets in different ways.  Whereas the coiled-coil domain of Climp63 inserts into the lumen of the 
ER and aids in attachment of the two apposed membranes holding them at a fixed distance from 
each other, the coiled-coil domains of both p180 and kinectin are extra-lumenal and are proposed 
to maintain the flatness of the ER sheets (166).  There is also evidence that the presence of 
ribosomes on ER sheets is important in formation and/or stabilization of sheet morphology (164, 
167).  
1.5 ENDOSOME MATURATION 
Endosomes are the intracellular membrane-bound vesicles resulting from cellular endocytosis.  
They function to recycle cellular components to and from the plasma membrane and/or to shuttle 
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cellular components to lysosomes for degradation.  Endosome maturation begins with fusion of 
incoming endocytic vesicles to form early endosomes (EE).  The membrane of the EE contains 
Rab5 and a phosphatidylinositol 3- kinase (PI3K) complex responsible for converting the lipid 
phosphatidylinositol (PI) to phosphatidylinositol 3- phosphate (PI3P).  Both Rab5 and the PI3K 
complex are important markers of immature EE, and serve to recruit factors necessary for cargo 
sorting as well as fusion and maturation of the EE (168-170).  As PI3P accumulates in the 
membrane of the EE, EEA1 is recruited, which marks the EE as mature (171).  Most EEs are small 
compared to late endosomes (LE) and lysosomes, and exist in the periphery of the cell close to the 
plasma membrane (172, 173).  Interestingly, as endosomes mature they become larger due to 
fusion events, migrate towards the perinuclear region of the cell, become more closely associated 
with the ER, and become progressively more acidic (159, 174). 
 Maturation of EE to LE involves what is known as a ‘Rab switch’, in which Rab5 recruits 
Rab7 resulting in loss of Rab5 from the LE (175, 176).  This switch begins maturation to LE and 
therefore commitment of the endosome to later fusion with a lysosome for cargo degradation rather 
than recycling of cargo back to the plasma membrane.  Maturation of LE also involves further 
conversion of the endosomal membrane phosphoinositides to phosphatidylinositol (3,5)-
phopshate-2 (PI(3,5)P2), with accumulation of PI(3,5)P2 in the membrane indicative of 
progression to LE (177, 178).  This is important for further endosomal maturation because 
PI(3,5)P2 recruits a different profile of effector proteins to the membrane of the LE than PI3P 
recruits to the membrane of EE, directing the differential functions of EE vs. LE.  Notably, 
inhibition of PI conversion leads to a highly vacuolated phenotype and enlarged endosomes (179-
181).  The final step in the degradative endocytic pathway is fusion of the LE with a lysosome, 
which contains low pH and degradative enzymes. 
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 1.6 BPI/LBP PROTEIN FAMILY 
1.6.1 BPI 
Bactericidal permeability increasing protein (BPI) is an inducible cationic antimicrobial peptide 
expressed in several types of leukocytes, fibroblasts and epithelial cells (182-185).  It exerts its 
antimicrobial function by binding to the Lipid A motif of the lipopolysaccharide (LPS) present 
on the exterior of all gram-negative bacteria, effectively neutralizing the endotoxicity of LPS and 
opsonizing the bacterium for phagocytosis by immune cells (186).  It also exerts direct 
antimicrobial activity by damaging bacterial membrane integrity thus leading to bacterial 
cytotoxicity (187).  The crystal structure of BPI has been solved, and reveals a 55 kDa 
boomerang-shaped structure (Figure 5, (188)), the N-terminus of which contains the lysine-rich 
cationic region responsible for LPS-neutralizing and direct anti-bacterial activity (189).  The C-
terminus contains the opsonizing activity (190).   
1.6.2 LBP 
LPS-binding protein (LBP) is a member of the BPI/LBP family of proteins and shares significant 
primary structural homology to BPI.  LBP also plays a significant role in lipid recognition and host 
defense, however its role is seemingly antagonistic to that of BPI.  It is an anionic protein residing 
in the plasma that enhances immune responses to monomeric LPS by binding and delivering it to 
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the TLR4/CD14/MD2 receptor complex (191, 192).  Although they are structurally similar, it is 
differences in the C-termini of BPI and LBP that determine their differential functions (193).  The 
higher affinity of BPI for LPS as well as its concentrated presence at sites of high inflammation 
favor the binding of the antimicrobial and endotoxin neutralizing BPI to LPS, and therefore 
precludes the ability of LBP to cause an excessive amount of inflammation in response to LPS 
(194, 195).  This is also achieved simply by the binding of aggregated LPS by BPI preventing its 
disassociation into monomers, and therefore preventing the binding of LBP to monomeric LPS 
(196).       
1.6.3 BPIFB3/LPLUNC3    
BPIFB3 (RYA3, LPLUNC3) was originally described in rats as a lipid-binding protein 
exclusively found in olfactory mucosa. Due to its lipid-binding properties and its expression 
pattern in rats it was proposed to be an oderant-binding protein (197). This initial 
characterization was later expanded when it was genetically mapped to a region about 5 Mb 
upstream of the bactericidal permeability increasing (BPI)/LPS-binding protein (LBP) family of 
lipid binding and antimicrobial genes. The RY gene cluster and other genes of the BPI/LBP 
family share significant sequence homology, including cholesterylester transfer protein (CETP) 
and phospholipid transfer protein (PLTP), both of which are involved in lipid transport in plasma 
(198). Around the same time the RY gene cluster was described, the PLUNC subfamily of 
BPI/LBP proteins (palate, lung and nasal epithelium clone) was discovered, consisting of at least 
10 different proteins with predicted expression in humans (199-201). They are described as BPI 
homologs expressed at mucosal surfaces, although little is known about their function. They 
appear to have the ability to bind to bacteria and LPS, but do not directly neutralize or kill 
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bacteria (202).  The PLUNC proteins are divided into two groups, the long (LPLUNC) and short 
(SPLUNC). LPLUNCS have sequence and structure homology to both the LPS-binding N-
terminus and the C-terminus of BPI (Figure 5, (188)), which is responsible for its opsonization 
activity, and SPLUNCS have homology to only the N-terminal half of BPI (200). The RY genes 
were reported to be members of the PLUNC family (LPLUNC2-4), RYA3 (BPIFB3) as 
LPLUNC3 (203). BPIFB3 has not been functionally characterized, and any assigned putative 
function is largely due to its homology with lipid-binding antimicrobial proteins of the LBP/BPI 
superfamily and its previously reported expression profile in olfactory mucosa. 
 
 
 
Figure 5. Structure of bactericidal permeability increasing protein (BPI). 
The structure of BPI is described as a boomerang shape, with lipid-binding regions at both the C- and N-termini.  
BPIFB3 is reported to contain a similar structure.  From Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1997. Crystal 
structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 276:1861-1864.  Reprinted 
with permission from AAAS. 
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2.0  STATEMENT OF THE PROBLEM 
To develop therapeutics for viral infections, it is crucial to understand the relationships between 
viruses and host cells, because this complex interplay often dictates the outcome of infection at 
both the cellular and organismal levels.  There are many different steps in a virus’ lifecycle that 
lead to interactions with components of the host cell it is invading.  Some of these interactions are 
beneficial to the virus or crucial for completion of its life cycle, and others are detrimental to the 
virus and serve to aid the host cell in recognition and eradication of virus infection.  For example, 
the RLRs are host proteins that reside in the host cell cytoplasm and recognize foreign nucleic acid 
derived from viral infection, resulting in initiation of an anti-viral state that is detrimental to the 
virus.  Conversely, all positive-sense RNA viruses are known to utilize host cell-derived 
membranes to facilitate their replication and thus successful completion of the viral life cycle.  To 
identify novel regulators of enterovirus replication, we previously performed a high-throughput 
RNAi screen (HTS) using human brain microvascular endothelial cells (hBMECs), an in vitro 
model of the blood brain barrier (204).  We chose two screen ‘hits’ for follow-up (Gp78 and 
BPIFB3), and hypothesized that they were novel regulators of enterovirus infection that may 
function more broadly in the life cycles of other unrelated viruses as well. 
Aim 1: Define the role of Gp78 in regulating enterovirus replication.  Gp78 exists both 
at the cell membrane where it regulates motility in response to autocrine motility factor binding 
and at the mitochondria-ER interface where it acts in the ERAD pathway as an E3 ubiquitin ligase.  
In this aim we showed that Gp78 depletion restricts infection of two unrelated RNA viruses, CVB 
and VSV.  We went on to show that Gp78 negatively regulates type I IFN signaling.  We showed 
that Gp78 regulates MAVS-mediated type I IFN signaling by two independent mechanisms: (1) 
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by specific and post-translational Gp78-mediated degradation of MAVS, a critical adaptor for 
RLR-mediated antiviral signaling; and (2) by protein-protein interaction between Gp78 and 
MAVS.  Gp78-mediated degradation of MAVS was proteasome-dependent and required the E3 
ubiquitin ligase activity of Gp78, and the Gp78-MAVS interaction required the RING domain of 
Gp78.  We therefore showed that Gp78 regulates enterovirus infection by modulating MAVS-
mediated type I IFN signaling, also providing a mechanistic explanation for this modulation. 
Aim 2: Characterize the role of BPIFB3 in enterovirus infection.  BPIFB3 (RYA3, 
LPLUNC3) is a largely uncharacterized protein of the BPI/LBP family of proteins. This family of 
lipid-binding antimicrobial proteins includes the PLUNC group of proteins, which has been 
described as a family of candidate host defense proteins in the upper airways. In this aim we 
showed that depletion of BPIFB3 in hBMECs significantly enhances enterovirus infection.  We 
went on to investigate its localization and showed that BPIFB3 localizes to the ER, and that this 
localization has consequences for ER morphology and calcium homeostasis since depletion of 
BPIFB3 resulted in disruption of ER morphology and ER-regulated calcium homeostasis.  In order 
to further unravel its role in virus infection, we examined the effect of BPIFB3 depletion on 
infection of a diverse group of viruses and show that whereas infection by the other enteroviruses 
PV and enterovirus 71 (EV71) is enhanced, infection by VSV and VV is restricted in the absence 
of BPIFB3. Additionally, VSV-mediated syncytia formation was enhanced in the absence of 
BPIFB3, a phenomenon that may correlate with an observed increase in size and number of cellular 
vesicles and endosomes/lysosomes.  Overall, these results led us to the conclusion that the 
disruptions of ER morphology and endo/lysosome trafficking likely account for the alterations in 
virus infection seen in the absence of BPIFB3.  
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In this study, we defined the specific functions of two of the potential novel regulators of 
enterovirus infection identified by HTS: Gp78 (AMFR), whose depletion significantly restricted 
infection, and BPIFB3 (RYA3, LPLUNC3), whose depletion significantly enhanced infection. We 
showed that these two proteins are crucial components of the virus-host cell interaction, playing 
previously uncharacterized roles in modulating viral infection. 
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3.0  MATERIALS AND METHODS 
3.1 CELLS AND VIRUSES 
HEK293T cells, human fibrosarcoma HT1080 cells, human osteosarcoma U2OS cells, HeLa cells, 
and Vero cells were cultured in DMEM-H supplemented with 10% FBS and 1× 
penicillin/streptomycin.  Human brain microvascular endothelial cells (HBMEC) were obtained 
from Dr. Kwang Sik Kim, and were cultured in RPMI 1640 supplemented with 10% FBS, 10% 
Nuserum, 1mM sodium pyruvate, non-essential amino acids, vitamins, and penicillin/streptomycin 
(1x), as previously described (204, 205).  Stable U2OS cells expressing BPIFB3-Flag were 
constructed by selection in G418 (500µg/mL) followed by isolation by limiting dilution.  
Experiments were performed with CVB3-RD at 3 plaque forming units (pfu)/cell (expanded as 
previously described (92)), PV Sabin 2 at 1 pfu/cell (previously described in (206)), recombinant 
GFP-expressing vesicular stomatitis virus Indiana at 2 pfu/cell (VSV, as described in (92)), and 
Sendai virus at 25 hemagglutination units (HAU)/mL (SeV, Cantell strain purchased from Charles 
River Laboratories).  Experiments measuring productive virus infection were performed with 0.5-
1 plaque forming units (pfu)/cell for ~16 hours. Plaque assays were performed as described 
previously (207). VV-YFP Western Reserve was obtained from Dr. Sara Cherry and has been 
described previously (208).  CellLight ER-RFP BacMam 2.0 baculovirus was purchased from 
Invitrogen.  
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3.2 VIRUS PREPARATIONS 
3.2.1 CVB3-RD 
HeLa cells (clone 7B) were plated in T-150 flasks and grown to confluence.  CVB3-RD was bound 
to the cells at room temperature for 1 hour in serum-free MEM containing 20 mM HEPES.  
Binding medium was then replaced with complete medium and the cells incubated until severe 
cytopathic effect was observed (16-24 hours).  Cells were lysed using three rounds of subsequent 
freezing and thawing followed by addition of 10% Triton-X-100, a debris spin, and addition of 
10% SDS.  Cleared virus-containing cell lysate was then spun in an ultracentrifuge on a 30% 
sucrose cushion using the SW28 rotor at ~30,000 rpm for 2.5 hours at 4ºC.  Virus was then 
resuspended in 1mL PBS and titered by plaque assay.     
3.2.2 VSV-GFP Indiana 
Vero cells were plated in T-150 flasks and grown to confluence.  VSV-GFP Indiana (0.01 pfu/mL) 
was bound to the cells at 37ºC for 1 hour in complete media containing 2% FBS.  Binding medium 
was then replaced with complete medium (2% FBS) and cells were incubated until severe 
cytopathic effect was observed (36-48 hours).  Virus-containing supernatant was subjected to a 
debris spin, and the cleared virus-containing supernatant was recovered and titered by plaque 
assay.   
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3.3 PLAQUE ASSAYS 
3.3.1 CVB 
At a time period of 24 hours prior to performing the plaque assay, HeLa 7b cells were plated in 
12-well plates at 1x106 cells/well.  Serial dilutions of CVB were bound to cells at room temperature 
for 1 hour in complete media.  The virus-containing binding media was removed and 0.8% agarose 
overlay containing 2X phenol-free MEM, FBS and Pen/Strep was added and allowed to solidify.  
After a 36-48 hour incubation at 37ºC, agarose plugs were removed, cells rinsed, and plaques 
visualized using crystal violet.  
3.3.2 VSV-GFP 
At a time period of 24 hours prior to performing the plaque assay, Vero cells were plated in 12-
well plates at 5x105 cells/well.  Serial dilutions of VSV-GFP were bound to cells at 37ºC for 1 
hour in complete media.  The virus-containing binding media was removed, cells washed with 
PBS, and 1.6% agarose overlay containing 2X phenol-free MEM, FBS, NEAA, and Pen/Strep was 
added and allowed to solidify.  After a 24 hour incubation at 37ºC, agarose plugs were removed, 
cells rinsed, and plaques visualized using crystal violet.  
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3.4 ANTIBODIES 
Mouse anti-enterovirus VP1 (Ncl-Entero) was obtained from Novocastra Laboratories.  Mouse 
anti-GFP (B-2), mouse anti-V5 (H-9), rabbit and mouse anti-Flag (OctA, D-8 or H-5), rabbit anti-
GAPDH (FL-335), and goat anti-Gp78 (N-18) were obtained from Santa Cruz Biotechnology.  
Rabbit anti-MAVS was obtained from Bethyl Laboratories.  Mouse monoclonal antibody to 
mitochondria (MTCO2) was obtained from Abcam.  Alexa fluor-conjugated secondary antibodies 
were from Invitrogen. Rat anti-Gp78 IgM (3F3A) was a generous gift from Dr. Ivan Nabi 
(University of British Columbia, Vancouver, Canada) and was previously described (129). 
3.5 PLASMIDS, SIRNAS AND TRANSFECTIONS 
Unless otherwise specified, all Gp78 constructs were of human origin.  pCI-Neo-gp78/JM20 was 
purchased from Addgene and was previously described (136). For subsequent cloning, the ORF 
of Gp78 was amplified by PCR from pCI-Neo-Gp78/JM20 using primers also encoding an N-
terminal Flag tag, and was then subcloned into pcDNA3.1 using BamHI and XbaI sites. C-terminal 
Gp78 mutants were generated by standard PCR cloning.  Primer sequences are available upon 
request.  Flag-tagged mouse Gp78 and the mouse Gp78 RING mutant were provided by Dr. Ivan 
Nabi and have been previously described (151).  EGFP-MAVS, EGFP-MAVS-CT and NT, EGFP-
RIG-I, V5-IRF3-5D and EGFP-STING have been described previously (92) (209).  Flag-tagged 
BPIFB3 was generated by amplification of BPIFB3 cDNA with primers encoding a C-terminal 
Flag tag and cloned into pcDNA3.1/V5-His TOPO TA as per the manufacturer’s instructions 
(Invitrogen). 
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The siRNA targeting Gp78 was purchased from Sigma Aldrich 
(GGACGAACUCCUCCAGCAAtt).  The siRNA used to target BPIFB3 
(GCUUAACGUGGCCCUGGAUtt) was also purchased from Sigma.  Control (scrambled) 
siRNAs were purchased from Ambion or Sigma. 
 Plasmid transfections were performed using X-tremeGENE 9 or HP (Roche) essentially 
per the manufacturer’s protocol. For siRNA transfections, HBMEC or HT1080 were transfected 
with siRNAs (final concentration 25-75 nM) using DharmaFECT-1 transfection reagent (Thermo-
Fisher Scientific) according to the manufacturer’s protocol. 
3.6 IMMUNOBLOTS 
Cells were grown to confluence in 24-well plates, and lysates prepared with RIPA buffer (50 mM 
Tris-HCl [pH 7.4], 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM 
phenylmethanesulfonyl fluoride, 1 mg/ml aprotinin, leupeptin, and pepstatin). Lysates (~30µg) 
were run on 4%–20% Tris-HCl gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose 
membranes. Membranes were blocked using 5% nonfat dry milk, probed with the indicated 
antibodies, and developed using horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology) and SuperSignal West Pico or Dura chemiluminescent substrates (Pierce 
Biotechnology).  Densitometry was performed using Image J (NIH). 
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3.7 IMMUNOPRECIPITATIONS 
Confluent HEK293T cells transiently transfected in 6-well plates with the indicated plasmids were 
lysed with 0.5mL RIPA buffer (450 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl [pH 7.8], 1% 
Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 0.5 μg/ml leupeptin, and 0.5 μg/ml pepstatin), 
and insoluble material was cleared by centrifugation.  350µL lysate was incubated with the 
indicated antibodies for 1-2 hr at 4°C followed by the addition of Sepharose G beads for an 
additional 1-2 hr at 4°C. After centrifugation, the beads were washed with RIPA buffer a minimum 
of five times and heated at 95 °C for 10 min in Laemmli sample buffer. Following a brief 
centrifugation, the entire supernatant was immunoblotted with the indicated antibodies. 
 
3.8 REPORTER-GENE ASSAYS 
Activation of IFN-β and NF-κB promoters was quantified using dual luciferase reporter-gene 
assays. Cells were transfected in 96-well plates with p-125 luc (which contains the entire IFN-β 
promoter upstream of firefly luciferase) or NF-κB reporter (which contains NF-κB responsive 
promoter elements upstream of firefly luciferase) plasmids together with a control renilla 
luciferase plasmid (pRL-null, Promega) and the indicated plasmids. Cells were lysed and prepared 
for luciferase measurement using the Dual-Luciferase assay kit (Promega) according to 
manufacturer’s instructions, and luciferase activity was measured using a Synergy 2 luminescence 
plate reader (Bio-Tek).  Data are presented as fold induction over uninfected or vector-transfected 
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controls, and are normalized to renilla luciferase activity. All experiments were performed in 
triplicate and conducted a minimum of three times. 
3.9 RT-QPCR 
Total cellular RNA was extracted using TRI reagent (MRC) according to manufacturer’s protocol.  
RNA samples were treated with RNAse-free DNAse (Qiagen) prior to cDNA synthesis. Total 
RNA (1µg) was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad).  RT-qPCR was 
performed using iQ SYBR Green Supermix (Bio-Rad) in an Applied Biosystems StepOnePlus 
real-time PCR machine. Gene expression was calculated using the 2-ΔΔCT method and was 
normalized to actin (210).  QuantiTect primers against Gp78 and BPIFB3 were purchased from 
Qiagen.  Primer sequences are reported in Table 2 below. 
 
Table 2. RT-qPCR primers. 
 
 
Gene Forward (5’-3’) Reverse (5’-3’) 
MAVS GTCACTTCCTGCTGAGA TGCTCTGAATTCTCTCCT 
Actin ACTGGCACGACATGGAGAAAA GCCACACGCAGCTC 
CVB ACGAATCCCAGTGTGTTTTGG TGCTCAAAAACGGTATGGACAT 
GFP CACATGAAGCAGCACGACTTCT AACTCCAGCAGGACCATGTGAT 
ISG56 CAACCAAGCAAATGTGAGGA AGGGGAAGCAAAGAAAATGG 
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 3.10 IMMUNOFLUORESCENCE AND ELECTRON MICROSCOPY 
Cells cultured in 8-well chamber slides (LabTek, Nunc) were washed and fixed with either 4% 
paraformaldehyde or with ice-cold methanol. Cells were then permeablized with 0.1% Triton X-
100 in phosphate buffered saline (PBS) and incubated with the indicated primary antibodies for 1 
hr at room temperature (RT).  Following washing, cells were incubated with secondary antibodies 
for 30 min at room temperature, washed, and mounted with Vectashield (Vector Laboratories) 
containing 4′,6-diamidino-2-phenylindole (DAPI).  Images were captured using a FV1000 
confocal laser scanning microscope (Olympus), analyzed using Image J (NIH) or FV10-ASW 
(Olympus) (Bitplane), and contrasted and merged using Photoshop (Adobe).  Electron microscopy 
was performed essentially as described (208).  Briefly, cells in 12-well plates were fixed with 2.5% 
glutaraldehyde for 1 hour at room temperature, and the remaining preparation steps performed by 
the University of Pittsburgh Center for Biological Imaging.  Samples were washed for 10 minutes, 
3 times in PBS.  The monolayers were post-fixed in 1% OsO4 with 1% potassium ferricyanide for 
1 hour at 4ºC, then washed again 3 times for 10 minutes each in PBS.  The monolayers were 
dehydrated in a graded series of alcohol (30%, 50%, 70%, 90%) for 10 minutes each, then three 
times in 100% ethanol for 15 minutes each.  Samples were then incubated three times in epon (1:1 
propylene oxide:Polybed 812 epoxy resin) for 1 hour each.  The samples were then embedded in 
molds, and subsequently cured at 37ºC overnight and 65 ºC for 48 hours.  Samples were then 
sectioned on mesh copper grids and microscopy performed on a JEOL JEM 1011 transmission 
electron microscope. 
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3.11 SUBCELLULAR FRACTIONATION 
Stable U2OS cells expressing BPIFB3-Flag were grown in a T-25 flask to confluence and 
fractionation performed using the Subcellular Protein Fractionation Kit for Cultured Cells from 
Pierce essentially per the manufacturer’s instructions. 
3.12 FLUO-4 AND FURA-2 IMAGING 
Ca2+ measurements were conducted essentially as described using either the ratiometric dye Fura-
2 AM or Fluo-4 AM (211).  For Fura-2 experiments, cells were plated 24 hours prior to the 
experiment in 35mm Mattek dishes.  The following day the cells were loaded with 1µM Fura-2 
AM for 30 minutes at 37ºC.  Cells were then rinsed 3 times in PBS (no calcium or magnesium). 
Cells were imaged live in 1 mL PBS (no calcium or magnesium) using an Olympus IX81 
motorized inverted microscope.  Images were acquired at excitations 340nm and 380nm every 5 
seconds for about 15 minutes using Slidebook 5.0 advanced imaging software.  Intensity ratios 
(340nm/380nm) for 30 selected regions of interest (ROIs)/dish were calculated using Slidebook 
and replicates averaged and plotted over time.  Thapsigargin (1µM) was added to stimulate ER 
calcium flux at 5 minutes after image capturing was begun. 
  For Fluo-4 experiments, cells were plated 24 hours prior to the experiment in 8 well 
chamber slides.  The following day the cells were loaded with 1µM Fluo-4 AM for 30 minutes at 
37ºC.  Cells were then rinsed 3 times in PBS (no calcium or magnesium).  Cells were imaged live 
in 1 mL PBS (no calcium or magnesium) using an Olympus IX81 motorized inverted microscope. 
Images were acquired every 5 seconds for about 10 minutes using Slidebook 5.0 advanced imaging 
45 
software.  Fluorescence intensity values for 30 selected regions of interest (ROIs)/well were 
plotted over time using Slidebook. Thapsigargin (1µM) was added to stimulate ER calcium flux 
at ~1.5 minutes after image capturing was begun. 
3.13 STATISTICAL ANALYSIS 
Data are presented as mean ± standard deviation or standard error of the mean.  Paired, or unpaired, 
two-tailed t-test or one-way analysis of variance (ANOVA) and Bonferroni’s correction for 
multiple comparisons were used to determine statistical significance (*p<0.01). 
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4.0  SPECIFIC AIM ONE:  DEFINE THE ROLE OF GP78 IN REGULATING 
ENTEROVIRUS INFECTION 
4.1 BACKGROUND 
Recognition of pathogen-derived nucleic acids is amongst the most important mechanisms by 
which a host cell defends against pathogen infection. Upon recognition of these nucleic acids, the 
transcription of myriad antiviral genes ensues, culminating in a cellular antimicrobial state that 
equips the cell to resist and/or suppress infection.  The cytosolic pattern recognition receptors RIG-
I and MDA5 are largely responsible for initiating the innate immune response to cytosolic dsRNA 
derived from the replication of viral pathogens (212).  The signaling initiated by one or both of 
these cytosolic sentinels converges on a common mitochondria-localized adaptor molecule, 
MAVS, which in turn leads to nuclear translocation of NF-κB and IRF-3 for induction of type I 
IFN production (65).  MAVS contains an N-terminal CARD, which is required for both upstream 
and downstream interactions, as well as a C-terminal mitochondrial localization sequence, which 
is required for downstream signaling events (63-66).   
         Because enhanced inflammation can lead to cell damage, mechanisms must exist to 
tightly regulate antiviral signaling. There are a variety of mechanisms by which regulators 
specifically modulate MAVS expression and/or signaling.  This can be achieved by protein-protein 
interactions that physically disrupt or enhance upstream or downstream interactions required for 
propagating MAVS-mediated signaling (87, 89, 91, 94, 97, 98, 213).  MAVS regulation can also 
be achieved by post-translational modifications such as ubiquitination that lead to inactivation or 
proteasomal degradation (77, 84, 88, 213).  Variations in mitochondrial dynamics have also 
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been reported to play a role in MAVS regulation, such as alterations in mitochondrial 
fusion/fission (75, 76), membrane potential (76), reactive oxygen species generation (95), and 
mitochondrial-endoplasmic reticulum contacts (MAMs) (75, 85).     
       MAMs are defined as sites of close physical contact (~10-30nm (214, 215)) between the 
ER and mitochondria. It is estimated that between 5-20% of mitochondria are in direct contact 
with the ER (216).  The MAM is an important cellular domain that regulates a variety of 
functions involved in cellular homeostasis such as lipid biosynthesis (217, 218), Ca2+ 
signaling, and cell survival pathways (219-221).  Quite interestingly, activated MAVS-
containing innate immune synapses form at MAMs, and the population of MAVS at the MAM 
is targeted by the hepatitis C virus (HCV) NS3/4A protease, underscoring the importance of this 
compartment in innate antiviral signaling (85). In addition, the mitochondria and MAM have 
been associated with the induction of inflammasome signaling (222). 
  The MAM proteome includes Gp78 (147-150), an E3 ubiquitin ligase active in the 
ER-associated degradation (ERAD) pathway.  Gp78 is also a cell surface receptor for the 
cytokine autocrine motility factor (AMF), the activity of which has been linked with 
increased cancer metastasis presumably due to its role in cell differentiation, survival and 
growth (126). Gp78 is responsible for conjugation of ubiquitin to misfolded proteins, which 
are then directed to the cytosolic proteasome for subsequent degradation (132, 135, 136). 
Gp78-mediated ERAD participation requires its C-terminal RING domain (responsible for 
ligase activity), Cue domain (responsible for binding of ubiquitin), and E2 (the enzyme 
responsible for bringing in the ubiquitin) binding site (132, 135, 136). The C-terminus of 
gp78 also contains a site of interaction with the AAA ATPase p97 (VCP), which provides the 
driving force for translocation of the polyubiquitinated substrates to the cytosol for subse-
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quent degradation by the proteasome (138-141). It has also been recently reported that Gp78 
induces mitochondrial fragmentation in a ligase-dependent manner, leading to mitophagy upon 
mitochondrial membrane depolarization (151).  
        Previously, we conducted RNAi high-throughput screening and identified Gp78 as a gene 
whose depletion led to a significant reduction in infection of the enteroviruses CVB and PV 
(205). In the current study, we provide a molecular mechanism for these previous findings and 
show that Gp78 is a novel regulator of RLR signaling.  We show that in addition to CVB and 
PV, depletion of Gp78 results in a robust decrease of VSV infection.  Mechanistically, we show 
that expression of Gp78 dramatically represses type I IFN signaling upstream of IRF3, and that 
this decrease in signaling corresponds to decreases in MAVS protein levels. Expression of Gp78 
mutants defective in E3 ubiquitin ligase activity or ERAD participation lost their ability to 
decrease MAVS levels, but surprisingly maintained their ability to repress RLR-mediated IFN-β 
signaling.  In contrast, Gp78 lacking its entire C-terminus lost both its ability to induce 
reductions in MAVS expression and repress RLR signaling. These studies point to an 
unexpected role for the MAM-localized Gp78 E3 ubiquitin ligase in the negative regulation of 
MAVS signaling. Our data implicate two parallel pathways by which Gp78 regulates MAVS 
expression and signaling—one pathway requires its E3 ubiquitin ligase and ERAD activity, 
while the other pathway occurs independently of E3 ubiquitin ligase and ERAD activity, but 
requires the Gp78 C-terminus and occurs via an association between this region and the N- and 
C-terminal domains of MAVS.  
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4.2 RESULTS 
4.2.1 Gp78 is a regulator of RNA virus infection 
We previously conducted high throughput RNAi screens for novel regulators of enterovirus 
infection in human brain microvascular endothelial cells (HBMEC) (205), and identified Gp78 as 
a regulator of CVB and PV infection whose depletion led to a robust (~3-fold) decrease of infection 
(205) (Figure 6A).  To expand on these findings, we also determined the effects of Gp78 depletion 
on CVB infection in the fibrosarcoma cell line HT1080 (a cell type reported to express high levels 
of Gp78 (223)).  Similar to our results in HBMEC, we found that RNAi-mediated Gp78 silencing 
decreased CVB infection about 3-fold (Figure 6C). In addition, we found that Gp78 silencing also 
reduced the infection of the unrelated RNA virus VSV, a member of the rhabdovirus family, about 
10-fold (Figures 6B and 6C). Efficient reduction of Gp78 expression in the presence of RNAi 
(~50%) was achieved in these experiments (Figure 6D). Taken together, these data show that 
depletion of Gp78 in both HBMEC and HT1080 cells results in a decrease of CVB, PV and VSV 
infection, suggesting a mechanism that is common to two independent families of RNA viruses in 
disparate cell types.  
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Figure 6. Gp78 depletion restricts RNA virus replication. 
 (A), Decreased CVB and PV replication by high-throughput RNAi screening in HBMEC transfected with Gp78 
siRNAs (siGp78) compared to an siRNA targeting a gene within the library that had no effect on viral replication (si-
No Effect). VP1 staining is shown in green and DAPI-stained nuclei are shown in blue. White text at bottom left 
denotes the level of infection (%). (B), Decreased VSV-GFP replication in HT1080 cells transfected with siGp78 
compared to control siRNA (siCON), as assessed by immunofluorescence microscopy at 8 hrs post-infection.  VSV-
GFP is shown in green and DAPI-stained nuclei are shown in blue. (C), Decreased VSV-GFP and CVB replication in 
HT1080 cells transfected with siGP78 compared to control siRNA (siCON), as assessed by immunofluorescence 
microscopy at 8 hrs (VSV-GFP) or 16 hrs (CVB) post-infection.  (D), Level of Gp78 expression in HT1080 cells 
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transfected with siGp78 compared to a control siRNA, as assessed by RT-qPCR 48 hr post-transfection. Data in (A) 
and (B) are representative of at least 3 independent experiments, and data in (C) and (D) are from at least 3 independent 
experiments and are presented as mean ± standard deviation (*p<0.01). 
4.2.2 Gp78 negatively regulates type I IFN signaling 
Because depletion of Gp78 resulted in a decrease of infection by two unrelated families of RNA 
viruses, we next determined whether Gp78 regulated some aspect of type I IFN signaling. We 
found that expression of exogenous Gp78 led to a significant decrease in Sendai virus (SeV)-
induced signaling to both the IFN-β (~3-fold) and NF-κB (~2-fold) promoters (Figure 7A and 7B). 
SeV is specifically recognized by RIG-I (139). In addition, we found that overexpression of Gp78 
greatly attenuated the induction of the interferon stimulated gene (ISG)-56 by both cytosolic poly 
(I:C) (~10-fold) or SeV infection (Figure 7C, 7E). In contrast, RNAi-mediated silencing of Gp78 
greatly enhanced this induction (~2-fold) (Figure 7D, 7E).  Of note, the expression levels of ISG56 
slightly increased in the absence of Gp78 (by ~16 fold) even without stimulation by SeV (Figure 
7D), which could point to a steady state regulatory role for Gp78 in type I IFN signaling.  Taken 
together, these data suggest a negative regulatory role for Gp78 in type I IFN signaling. 
          A common characteristic of many type I IFN mediators is their inducible expression upon 
treatment with virus infection, purified interferon and/or PRR agonists (65, 222, 224-226). Given 
the possible role of Gp78 in the regulation of type I IFN signaling, we determined if its expression 
was inducible under these conditions.  We found that expression of Gp78 was not induced by 
treatment with purified IFN-β or cytosolic poly (I:C) or by infection with SeV (Figure 7F), a result 
underscoring the possible steady state regulatory role for Gp78 in type I IFN signaling. 
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Figure 7. Gp78 regulates type I interferon signaling. 
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(A and B), Dual luciferase assays from 293T cells transfected with IFN-β (A) or NF-κB (B) promoted luciferase 
constructs and the indicated plasmids.  Cells were infected with SeV 24 hr post-transfection and luciferase activity 
was measured 16 hr post-infection.  (C and D), Levels of ISG56 in untreated 293T (C) or HT1080 (D) cells transfected 
with the indicated plasmids (C) or siRNAs (D), transfected with 500ng poly (I:C) (C), or infected with SeV (D) at 48 
hr post-transfection for 16 hr, as assessed by RT-qPCR. (E), Gp78 expression from 293T (overexpression) or HT1080 
(siRNA) cells transfected with the indicated plasmids (left) or siRNAs (right), as assessed by RT-qPCR. Data are 
presented as mean ± standard deviation and correspond to data shown in Figure (2C), (2D). (F), Level of Gp78 (left) 
or ISG56 (right) expression in untreated HT1080 cells, or cells transfected with 500ng poly (I:C), treated with 500 
U/mL IFN-β overnight, or infected with SeV for 24hrs, as assessed by RT-qPCR. All data besides (E) are 
representative of at least 3 independent experiments, data in (E) are from at least 3 independent experiments, and all 
data are presented as mean ± standard deviation (*p<0.01). 
 
4.2.3 Gp78 negatively regulates RLR signaling 
RLR signaling is one of the most important components of the type I IFN response to RNA viruses. 
Given that depletion of Gp78 restricted the replication of both CVB and VSV, and enhanced type 
I IFN signaling, we next investigated the role of Gp78 in RLR signaling.  We found that expression 
of exogenous Gp78 greatly decreased signaling to the IFN-β promoter induced by overexpression 
of RIG-I, MDA5, and MAVS (~10-fold) (Figure 8A).  However, exogenously expressed Gp78 
had no effect on signaling to the IFN-β promoter induced by overexpression of a constitutively 
active mutant of IRF-3 (IRF3-5D) (227) (Figure 8B).  These results suggest that Gp78 exerts its 
regulatory role within the RLR pathway upstream of IRF3 activation. 
 
 
 
 54 
  
 
 
Figure 8. Gp78 regulates RLR signaling. 
(A and B), Dual luciferase assays from 293T cells transfected with IFN-β promoted luciferase constructs, RIG-I, 
MDA5, MAVS (A), or IRF3-5D (B) and the indicated plasmids (vector or Gp78).  Luciferase activity was measured 
48 hr post-transfection.  All data are representative of at least 3 independent experiments and presented as mean ± 
standard deviation (*p<0.01). 
 
 
4.2.4 Gp78 expression results in the post-translational downregulation of MAVS 
Because silencing of Gp78 restricted the replication of CVB and VSV, which are detected by 
different RLRs (97, 228, 229), and because Gp78 expression abrogated RLR signaling upstream 
of IRF3, we next investigated the effect of Gp78 on the expression of various innate immune-
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associated components.  Strikingly, we found that overexpression of Gp78 resulted in a marked 
decrease in EGFP-MAVS protein levels by immunoblotting (Figure 9A). In contrast, expression 
of Gp78 had no effect on the expression of EGFP-RIG-I, V5-IRF3-5D, or the unrelated ER-
localized IFN signaling molecule EGFP-STING (Figure 9A).  Importantly, overexpression of 
Gp78 had no effect on MAVS mRNA levels, suggesting that the Gp78-mediated decrease in 
MAVS protein levels occurs post-translationally (Figure 9B).   
Because our previous results relied on the overexpression of MAVS, we also determined 
whether expression of Gp78 reduced levels of endogenous MAVS. Similar to our findings with 
exogenously expressed MAVS, we found that Gp78 also decreased the levels of endogenous 
MAVS in a dose-dependent manner (Figure 9C). In addition, we observed a pronounced loss of 
endogenous MAVS immunofluorescence in cells transfected with Gp78 (Figure 9D).   
 Given that Gp78 has been associated with mitochondrial fragmentation and mitophagy 
(151), we also determined whether overexpression of Gp78 would lead to the possible degradation 
of other mitochondria-localized components. We found that expression of Gp78 had no effect on 
the levels of the constitutive mitochondrial marker MTC02 (Figure 9E). Taken together, these data 
show that MAVS protein levels are post-translationally decreased in the presence of Gp78 in a 
specific manner that does not rely on mitophagy or mitochondrial fragmentation. 
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Figure 9. Gp78 specifically alters MAVS levels. 
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(A), Immunoblot analysis from 293T cells 48 hrs post-transfection with EGFP-MAVS, EGFP-RIG-I, V5-IRF3-5D, 
or EGFP-STING constructs and either vector or Gp78 constructs.  Antibodies directed against GFP or V5 were used.  
Immunoblotting for Gp78 (middle panel) is included to demonstrate transfection and GAPDH (bottom panels) is 
included as a loading control.  (B), Levels of MAVS in 293T cells transfected with vector or Gp78 as assessed by RT-
qPCR at 48 hrs post-transfection.  (C), Immunoblot analysis for endogenous MAVS 48 hrs post-transfection with 
increasing amounts of Gp78 construct (from 0µg to 2µg). Immunoblotting for Gp78 (middle panel) is included to 
demonstrate transfection and GAPDH (bottom panels) is included as a loading control.  (D), Immunofluorescence 
microscopy for endogenous MAVS in U2OS cells 48 hr post-transfection with Flag-Gp78 construct.  MAVS is shown 
in red and Flag-Gp78 is shown in green.  DAPI-stained nuclei are shown in blue.  White arrows denote areas of 
decreased MAVS staining in the presence of Gp78.  (E), Immunoblot analysis from 293T cells 48 hrs post-transfection 
with EGFP-MAVS construct and either vector or Gp78 constructs.  Antibodies directed against GFP and MTCO2 (an 
unrelated mitochondrial protein) are included as a measure of specificity, and immunoblotting for Gp78 (middle panel) 
is included to demonstrate transfection and GAPDH (bottom panels).  All data besides (B) are representative of at 
least 3 independent experiments and data in (B) are from at least 3 independent experiments and are presented as mean 
± standard deviation (*p<0.01). 
 
 
4.2.5 Gp78 colocalizes with MAVS and specifically targets the MAVS CARD 
Consistent with the work of others (148, 150), we found that exogenously expressed Gp78 partially 
localized with a marker of mitochondria (Figure 10A).  In addition, we found that endogenous 
Gp78 colocalized with endogenous MAVS, likely at the ER-mitochondria interface in uninfected 
cells and in cells infected with SeV (Figure 10B). MAVS contains a C-terminal domain that 
mediates its mitochondrial localization and is required for its activity, and an N-terminal CARD-
containing region that is required for upstream and downstream interactions (65).  In order to 
investigate which region of MAVS is required for Gp78-mediated degradation, we cotransfected 
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the Flag-Gp78 construct with either the full length MAVS construct (MAVS-WT), or with deletion 
mutant constructs of MAVS containing 148 N-terminal amino acids including the CARD (MAVS-
NT) or 391 C-terminal amino acids including the transmembrane domain, but lacking the CARD 
(MAVS-CT).  We found that expression of Gp78 induced a reduction in the expression of both 
MAVS-WT (~3-fold) and MAVS-NT (~2.5-fold), but had no significant effect on the expression 
of MAVS-CT (Figure 10C). These data suggest that the CARD-containing N terminus of MAVS 
is required for Gp78-mediated decreases in MAVS expression. 
 
 
 
 
Figure 10. Gp78 is localized at the mitochondria in close proximity to MAVS, and targets the CARD of MAVS. 
(A), Immunofluorescence microscopy of U2OS cells 48 hr post-transfection with the Flag-Gp78 construct.  
Mitochondria are shown in red and were stained with MTCO2 antibody and Gp78 is shown in green and was stained 
with a Flag-specific antibody.  (B), Immunofluorescence microscopy of endogenous MAVS and endogenous Gp78 in 
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U2OS cells in uninfected (Mock) or SeV infected HT1080 cells.  MAVS is shown in red, and Gp78 is shown in green 
and was stained using the 3F3A antibody specific for Gp78. (C), Top, schematic of MAVS constructs used.  Bottom, 
immunoblot analysis from 293T cells 48 hrs post-transfection with EGFP-MAVS, EGFP-MAVS-CT, or EGFP-
MAVS-NT constructs with either vector or Gp78 constructs.  Antibody directed against GFP was used.  
Immunoblotting for Flag and GAPDH (bottom panel) are included to show expression of Gp78 and as a loading 
control, respectively.  Table at bottom, densitometry (MAVS/GAPDH normalized to vector control) in cells 
transfected with vector of Gp78. All data are representative of at least 3 independent experiments. 
 
 
4.2.6 Gp78-mediated degradation of MAVS requires its E3 ubiquitin ligase and ERAD 
activity 
Several domains within the C-terminus of Gp78 are critical for its E3 ubiquitin ligase and ERAD 
activities (schematic, Figure 11A, left).  These include a RING finger domain, a CUE domain, an 
E2-binding region (G2BR) (132, 135, 136), and a VCP-interacting motif (VIM) for translocation 
of the polyubiquitinated substrates to the cytosol for subsequent degradation by the proteasome) 
(138-141).  We next sought to determine the role of the E3 ubiquitin ligase and ERAD functions 
of Gp78 in its degradation of MAVS using a panel of point and truncation mutants (schematic, 
Figure 11A, right).  When MAVS was cotransfected with human or mouse Gp78 constructs 
(hGp78 or mGp78, respectively), a robust decrease in MAVS protein levels (~3-fold each) was 
evident by immunoblotting (Figure 11B, compare lane 1 to lanes 2 and 3).  However, MAVS 
protein levels were unaffected by a point mutant of mGp78 described previously (151) that 
abolishes its E3 ligase activity (mGp78 RING mut) (Figure 11B, compare lane 1 to lanes 3 and 4). 
Furthermore, truncation mutants of hGp78 that have been described previously to inhibit its 
 60 
participation in the ERAD pathway (135, 136) (lacking the VIM (∆VCP), VIM and G2BR 
(∆G2BR), VIM, G2BR and CUE (∆CUE), or the entire C terminus (∆C)), lost their ability to 
decrease MAVS (Figure 11B, compare lane 1 to lanes 4-8).  Importantly, when treated with 
MG132 (a proteasome inhibitor), MAVS protein levels were partially restored (~2.5 fold 
restoration) in the presence of Gp78 (Figure 11C).  Interestingly, consistent with the work of others 
(225), we found that MAVS protein levels (Figure 11D), but not RNA levels (not shown), were 
significantly decreased in response to SeV infection. Together, these data point to a role for the E3 
ubiquitin ligase and ERAD activity of Gp78 in MAVS degradation. 
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Figure 11. The E3 ubiquitin ligase activity of Gp78 and its association with the ERAD pathway is required 
for Gp78-mediated MAVS degradation. 
(A), Left panel, schematic of Gp78 showing important regions for E3 ubiquitin ligase activity.  Right panel, schematic 
of the C-terminus of Gp78 illustrating deletion mutants used in this panel.  (B), Immunoblot analysis from 293T cells 
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48 hrs post-transfection with EGFP-MAVS and the indicated plasmids.  Antibody directed against GFP was used.  
Immunoblotting for Flag and GAPDH (bottom panel) are included to show expression of wild-type and mutant Gp78 
and as a loading control, respectively. Table at bottom, densitometry (MAVS/GAPDH normalized to vector control) 
for cells transfected with the indicated plasmids. Densitometry was performed and data are presented as fold-change 
from vector untreated cells (bottom panel).  (C), Immunoblot analysis from 293T cells 48 hrs post-transfection with 
EGFP-MAVS and either vector control or Gp78.  MG132 (20 µM) was added 16 hours post-transfection.  Antibodies 
directed against GFP and GAPDH were used. Table at bottom, densitometry (MAVS/GAPDH normalized to vector 
control) in cells transfected with the indicated plasmids and either Mock- or MG132-treated. (D), Immunoblot analysis 
of MAVS (top) from 293T cells infected with SeV (50 or 100 HAU/mL) for ~24hrs. Immunoblotting for actin (bottom) 
is included as a loading control. Table at bottom, densitometry (MAVS/Actin normalized to control (mock infection).  
Data in 11D were provided by Dr. Saumendra Sarkar. 
 
 
4.2.7 Gp78-mediated abrogation of MAVS-mediated signaling occurs independently of 
E3 ubiquitin ligase and ERAD activities 
We found that the E3 ubiquitin ligase and ERAD activities of Gp78 were required for its 
degradation of MAVS.  Thus, we next determined whether this activity was also required for 
Gp78-mediated abrogation of type I IFN signaling. Surprisingly, we found that most of the mutants 
of Gp78 that ablated its ability to alter MAVS expression (mGp78 RING mut, hGP78-∆VCP, -
∆G2BR, and -∆CUE), retained their ability to suppress SeV-induced IFN-β signaling (Figure 
12A). In contrast, only the hGp78 mutant lacking almost the entire C-terminus (hGP78-∆C) lost 
the ability to attenuate antiviral signaling (Figure 12A). These data suggested that there are 
divergent mechanisms by which Gp78 induces MAVS degradation and attenuates MAVS-
mediated signaling. 
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4.2.8 The C-terminus of Gp78 interacts with MAVS and binds to both the N- and C-
terminal domains of MAVS 
There are several pathways by which cellular components attenuate MAVS-mediated signaling.  
One of these includes the use of specific protein-protein interactions to inhibit the binding of key 
upstream and/or downstream innate immune signaling components to MAVS (87, 94, 98). Given 
that Gp78 localizes in close proximity to MAVS (Figure 9B) and can attenuate MAVS-mediated 
signaling even in the absence of Gp78-mediated degradation (Figure 12A), we next determined 
whether Gp78 and MAVS form an interaction by performing coimmunoprecipitation studies. For 
these studies, we utilized the ∆VCP, ∆CUE, and ∆C mutants of Gp78, but not wild-type Gp78, to 
avoid experimental difficulties related to the decrease in MAVS levels mediated by full length 
Gp78. We found that MAVS coimmunoprecipitated with both Gp78-∆VCP and Gp78-∆CUE 
(Figure 12B). In contrast, MAVS did not coimmunoprecipitate with Gp78-∆C, despite this 
modification not significantly altering its localization (Figure 12B, 12C). These data suggest that 
Gp78 utilizes a domain between amino acids 311 and 455 of its C-terminus, most likely its RING 
region, to interact with MAVS.   
Both the N- and C-terminal domains of MAVS play critical roles in its activation by 
upstream components and propagation of downstream signals. For example, whereas both RIG-I 
and MDA5 bind to the N-terminal CARD of MAVS (65), tumor necrosis factor (TNF) receptor-
associated factor (TRAF)-3 binds to a region within the C-terminus of MAVS (230). Because we 
observed an association between Gp78 and MAVS, and a possible ablation of MAVS-mediated 
signaling as a result of this interaction, we next determined whether Gp78 interacted with the N- 
or C-terminal regions of MAVS. We found that Gp78-∆VCP interacted with both the N- and C-
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terminal domains of MAVS, whereas we did not detect any association of either of these domains 
with Gp78-∆C, as expected (Figure 12D). These data show that Gp78 utilizes a region within its 
C-terminus to interact with multiple regions of MAVS.  
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Figure 12. The C-terminus of Gp78 interacts with the N- and C-terminal regions of MAVS and is required 
to ablate MAVS-mediated signaling. 
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(A), Dual luciferase assays from 293T cells transfected with IFN-β promoted luciferase constructs and the indicated 
plasmids (a schematic of these constructs is shown in Figure 6A, right).  Cells were mock-infected or infected with 
SeV 24 hr post-transfection and luciferase activity was measured 16 hrs post-infection. (B), Immunoblot analysis from 
293T cells immunoprecipitates transfected with EGFP-MAVS and the indicated plasmids.  Immunoprecipitation was 
performed with anti-Flag antibody and immunoblotting was performed with anti-GFP antibody. Input (GFP) is shown 
at bottom. (C), Immunofluorescence microscopy for Flag-Gp78 wild-type (left) or ∆C (right) (in green) ~24hrs 
following transfection in U2OS cells.  Mitochondria are shown in red and were detected using anti-MTCO2. DAPI-
stained nuclei are shown in blue. (D), Immunoblot analysis from 293T cells immunoprecipitates transfected with 
EGFP-MAVS-NT or -CT and either vector, Flag-Gp78 ∆VCP, or Flag-Gp78-∆C.  Immunoprecipitation was 
performed with anti-Flag antibody and immunoblotting was performed with anti-GFP antibody. Input (GFP) is shown 
at bottom. Arrows denote NT and CT fragments and ns denotes a nonspecific band. Data are representative of at least 
3 independent experiments and data in (A) are presented as mean ± standard deviation (*p<0.01). 
4.3 DISCUSSION 
Here we report on the regulation of MAVS expression and signaling by the MAM-associated E3 
ubiquitin ligase Gp78. We identified Gp78 initially using an unbiased high throughput RNAi 
screen to identify novel regulators of enterovirus infection (205). In the follow-up studies 
presented here, we found that RNAi-mediated silencing of Gp78 also restricted VSV infection and 
correlated with enhancements of type I IFN antiviral signaling. Mechanistically, we found that 
Gp78 alters RLR signaling by both enhancing the degradation of MAVS via its E3 ubiquitin ligase 
and ERAD-mediated functions and by specifically interacting with MAVS via a region within its 
C-terminus. Collectively, these data report on the unexpected role of Gp78 in the regulation of 
MAVS-mediated antiviral signaling and suggest that it specifically functions to attenuate antiviral 
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signaling of MAVS at the MAM by two parallel pathways (reviewed in the schematic shown in 
Figure 13).  
    Whereas CVB and other enteroviruses are sensed by MDA5, RLR-mediated anti-
VSV signaling is specifically mediated by RIG-I (97, 228, 229).  Our findings that Gp78 
depletion suppressed infection by both viruses supports its specific regulation of an 
innate-immune associated factor common to both viruses, such as MAVS. Regulation of 
antiviral signaling at the mitochondrial level is quite strategic given that signals propagated by 
two independent cytosolic sensors converge on MAVS at the mitochondrial membrane. 
Therefore, regulators of MAVS such as Gp78 exert a higher level of control than they might if 
they targeted upstream components of RLR signaling such as RIG-I or MDA5 individually.  
          The MAM is emerging as a critical platform for MAVS-mediated innate antiviral signaling 
(85).  In light of evidence that the active population of MAVS in virus-infected cells is localized 
to the MAM (85, 148, 150), negative regulation of MAVS in this compartment is critical to 
prevent excessive inflammation.  Therefore, MAM-localized Gp78 is an ideal candidate to 
negatively regulate MAVS.  Interestingly, we found that type I IFN signaling is enhanced in the 
absence of Gp78 in uninfected cells.  This could indicate that Gp78 plays a ‘housekeeping role’ 
in the regulation of MAVS signaling to suppress MAVS-mediated innate immune signaling 
under basal states, likely as a means of avoiding hyperinflammatory signaling. This notion is 
supported by our findings that Gp78 expression is not induced by purified IFN-β treatment, 
transfection of cells with a synthetic ligand of RLR signaling, or SeV infection. Given the lack 
of a robust induction of Gp78 in response to any RLR ligand, it is possible that other interferon-
inducible regulators of MAVS exist within the MAM, and that these would be important for 
immediate regulation during an acute viral infection.  However, in the event of excessive 
inflammation after a viral infection has been 
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contained, or in the context of excessive inflammation in the absence of a viral threat (i.e., 
autoimmunity), negative regulation of MAVS at the MAM by a steady-state protein such as Gp78 
would become critical for cellular homeostasis.  
Ubiquitin–mediated proteasomal degradation of MAVS is a known mechanism for its 
negative regulation (75, 77, 84, 88, 231). Moreover, Gp78 is a well-characterized E3 ubiquitin 
ligase of the ERAD pathway.  Given that Gp78-induced degradation of MAVS was E3 ubiquitin 
ligase- and ERAD-dependent, and that the effect was partially rescued with the proteasome 
inhibitor MG132, we conclude that Gp78-mediated MAVS degradation is achieved at least in part 
by its Gp78-mediated ubiquitination and proteasomal degradation. Whereas the RING, Cue, and 
G2BR regions are important for the E3 ubiquitin ligase activity of Gp78 (135, 136), the VIM 
region is not required for the enzymatic addition of ubiquitin to the substrate and is instead required 
for translocation of the ubiquitinated substrate out of the ER membrane and to the cytosol for 
completion of the ERAD pathway (138-141).  Importantly, mutant Gp78 lacking this domain did 
not degrade MAVS, supporting a specific role for ERAD in MAVS degradation. The ERAD 
pathway is an ER-specific mechanism of protein quality control, and is mainly responsible for 
destruction of misfolded proteins exiting the ER by marking them with ubiquitin for proteasomal 
degradation (133).  Although the requirement of the VIM region seems to point to a role for the 
ERAD pathway in Gp78-mediated MAVS degradation, it is important to note that MAVS is a 
membrane-localized protein in the mitochondria that, like ERAD substrates in the ER, would 
require translocation into the cytosol for interaction with the proteasome even in the absence of 
traditional ERAD.  In fact, there are specific substrates recognized and negatively regulated by 
Gp78-mediated ubiquitination and proteasomal degradation in a manner distinct from ERAD’s 
traditional role of non-specific protein quality control (143, 144), including MAVS. 
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We show that the CARD-containing N-terminal region of MAVS, but not the C terminal 
region of MAVS, is targeted for Gp78-mediated degradation.  However, RIG-I, which also 
contains CARDs that are subject to ubiquitination (232), is not sensitive to Gp78-mediated 
degradation.  These data point to the specificity of the Gp78-mediated degradation of MAVS and 
suggest that it may not target all CARDs. In addition, as we observed degradation of MAVS-NT, 
this suggests that the mitochondrial localization of MAVS is not required for its degradation 
mediated by Gp78. 
Surprisingly, we observed a repression of MAVS-mediated signaling by Gp78 mutants 
incapable of participating in the ERAD pathway.  We show that Gp78 binds to both the N- and C-
terminal regions of MAVS, and that the region of Gp78 required for this binding is within RING-
containing residues 311-455, as binding was lost when these residues were removed.  Because 
RING domains are known to mediate protein- protein interactions (233, 234), it is likely that this 
region of Gp78 mediates its interaction with MAVS. Protein-protein interaction is a well-defined 
mechanism of regulating MAVS-mediated signaling.  This is often achieved by physically 
blocking key interactions of MAVS with up or downstream signaling partners (87, 89, 91, 94, 98).  
It is possible that binding of Gp78 to MAVS within its CARD would disrupt the interaction 
between MAVS and RIG-I/MDA5 that is required for downstream signaling (63-66).  However, 
it is also possible that Gp78 binds to a different region of MAVS, such as the proline rich region 
or TRAF interaction motifs (TIMs) required for MAVS interaction with the downstream signaling 
adaptors TRAF2/3/5/6 (66, 230, 235, 236), effectively disrupting and suppressing signaling. In 
addition, Gp78 may inhibit some aspect of MAVS oligomerization, which has been shown to play 
an important role in its signaling (101, 237, 238). 
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Taken together, our study provides evidence for two possible mechanisms for the 
regulation of MAVS expression and signaling by Gp78.  The first mechanism requires the ERAD 
activity of Gp78 and likely corresponds to enhancements in MAVS ubiquitination and proteasomal 
degradation while the second occurs independently of ERAD function, but requires Gp78–MAVS 
interactions (Schematic, Figure 8).  Both of these mechanisms likely require physical interaction 
of Gp78 with MAVS. These results shed light on a novel function of Gp78 in the regulation of 
MAVS-mediated antiviral signaling. Moreover, our work suggests that other MAM-localized 
components might also serve to specifically target MAVS as a means to regulate inflammatory 
signaling within the cell. Defining the specific components of the MAVS ‘regulome’ specifically 
within the MAM will undoubtedly provide exciting new insights into the regulation of antiviral 
signaling. 
 
 
 
Figure 13. Schematic of the proposed mechanisms of Gp78-mediated regulation of MAVS signaling. 
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Based on the data presented here, we propose a model by which MAM-associated Gp78 regulates MAVS signaling 
by two mechanisms: (1) protein-protein interactions and (2) ubiquitin-mediated degradation. In (1), Gp78 binding to 
MAVS might prevent its association with upstream (RIG-I/MDA5) or downstream (TRAF3/TRAF6) components 
associated with antiviral signaling. In (2), Gp78 utilizes its E3 ubiquitin ligase and ERAD functions to induce the 
degradation of MAVS. Although not specifically depicted in this schematic, MAVS oligomerization is a critical 
component of its signaling (101, 237, 238). 
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5.0  SPECIFIC AIM TWO: CHARACTERIZE THE ROLE OF BPIFB3 IN 
ENTEROVIRUS INFECTION 
5.1 BACKGROUND 
A newly emerging theme in ER function includes its role in the replication of viruses.  This 
phenomenon was first observed decades ago by electron microscopy when it was noticed that the 
intracellular membranes of PV-infected cells were morphologically different than that of 
uninfected cells, and it was concluded that viruses must induce some sort of membrane 
rearrangement upon infection (239-241).  It has since been shown that many viruses, including all 
positive-sense RNA viruses, hi-jack host-derived membranes for their replication (26-28), 
commonly from the ER or secretory system.  It is believed that this strategy serves to form 
scaffolding on which to assemble the replication machinery as well as protect the replicating RNA 
from cytosolic immune surveillance.  Picornaviruses, including PV and CVB, form double 
membrane-bound vesicular replication complexes derived from the ER, Golgi, and lysosomes (18, 
239-243).  It has been shown that CVB replication begins on the membranes of the Golgi and 
trans-Golgi network.  With the production of new viral proteins the secretory system is arrested 
and reorganized to provide a source for more viral replication complexes, and additional 
replication complexes are formed close to ER exit sites (19, 20). 
The rhabdovirus VSV is a single-stranded negative-sense RNA virus that has also been 
shown to utilize host-derived membranes.  During replication the virus was shown to form 
cytoplasmic inclusion bodies for the purpose of compartmentalization of replication (244-246).  
Early in the replication cycle these inclusion bodies do not seem to be enclosed by a membrane, 
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but later on in viral replication these inclusion bodies are enclosed by membranes derived from 
the ER (244).   
 The use of host-derived membranes for viral replication is not limited to RNA viruses, as 
the poxvirus VV was shown to also utilize this phenomenon for its replication.  VV is a large DNA 
virus that, unlike all other DNA viruses, replicates its DNA in the cytoplasm of the host cell, and 
its replication centers are typically organized into foci (247, 248).  Later EM studies showed that 
these foci of DNA replication are surrounded by rough ER, resembling mini-nuclei in the 
cytoplasm due to DNA labeling of the interior of the foci (249).      
Previously, we conducted RNAi high-throughput screening and identified BPIFB3 
(LPLUNC3, RYA3) as a gene whose depletion led to a significant enhancement in infection of 
the enteroviruses CVB and PV (205).  BPIFB3 belongs to the PLUNC group within the BPI/ 
LBP family of proteins, whose members include host defense proteins in the upper airways (197-
203).  We found this target particularly interesting since BPIFB3 has not been functionally 
characterized and sequence and structural analyses point to a role in lipid content and/or 
localization due to the presence of lipid-binding regions.  In these studies, in order to further 
characterize BPIFB3 and its role in enterovirus infection we first showed that CVB infection was 
enhanced in the absence of BPIFB3.  We went on to analyze the previously unreported 
subcellular localization of BPIFB3 and found that it is localized to the ER, and that depletion of 
BPIFB3 resulted in a severe disruption of the architecture and calcium homeostasis function of 
the ER.  In an attempt to further unravel the role of BPIFB3 in enterovirus infection we found 
that the infection of several other enteroviruses, as well as VSV and vaccinia virus, were greatly 
affected by the depletion of BPIFB3.  Taken together, in this work we have provided 
characterization of a previously undescribed and novel component of the ER that appears to be 
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crucial in regulation of infection of diverse viruses, possibly by affecting their ability to co-opt 
host membranes required for replication or trafficking. 
  
5.2 RESULTS 
5.2.1 Depletion of BPIFB3 results in a dramatic increase in CVB infection 
We previously conducted high throughput RNAi screens for novel regulators of enterovirus 
infection in hBMECs and identified BPIFB3 as a regulator of CVB and PV infection whose 
depletion led to a robust enhancement of infection (205).  Figure 14A shows recapitulation of the 
screen results in hBMECs, confirming that depletion of BPIFB3 in hBMECs leads to a robust 
enhancement of CVB infection.  This result was further confirmed using plaque assay to compare 
the titer of CVB propagated in hBMECs transfected with a control siRNA to the titer of CVB 
grown in hBMECs transfected with siBPIFB3.  Depletion of BPIFB3 resulted in nearly a log10 
increase in resulting CVB titers (Figure 14B).  Efficient knockdown of BPIFB3 was achieved 
(~50%), as measured using qPCR of BPIFB3 expression in cells transfected with siBPIFB3 and 
siCON (Figure 14C).  Together, these results show that BPIFB3 plays a role in CVB infection.       
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Figure 14. Confirmation of BPIFB3 as a regulator of CVB infection. 
(A), Enhanced CVB infection in hBMECs transfected with an siRNA targeting BPIFB3 (siBPIFB3) compared to cells 
transfected with a control siRNA (siCON).  Enteroviral VP1 is shown in green and DAPI-stained nuclei are shown in 
blue.  (B), Titers (pfu/mL) of CVB propagated for ~16 hrs on hBMECs transfected with siBPIFB3 or siCON.  (C), 
Knockdown efficiency of siBPIFB3 as measured using qPCR. Data in (A) are representative of at least 3 independent 
experiments, and data in (B) and (C) are from at least 3 independent experiments and are presented as mean ± standard 
deviation (*p<0.05). 
5.2.2 BPIFB3 is localized to the endoplasmic reticulum 
Many members of the BPI/LBP family, including BPIFB3, are largely uncharacterized and their 
localization patterns undetermined.  In order to provide clues to the role of BPIFB3 in viral 
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infection we examined the subcellular localization of BPIFB3. U2OS cells stably expressing 
BPIFB3-Flag were co-stained for early endosomes (EEA1), Golgi, lipid droplets (BODIPY), 
mitochondria and ER.  BPIFB3 highly co-localized only with a marker of the ER shown by 
immunofluorescence staining (Figure 15A), and its localization to the membrane/organelle 
fraction (i.e., ER-containing fraction, as shown by calnexin expression) was confirmed using 
subcellular fractionation of U2OS cells stably expressing BPIFB3-Flag (Figure 15B).   
 
 
 
 
Figure 15. ER localization of BPIFB3. 
 77 
(A), Top, schematic of BPIFB3-Flag, courtesy of Dr. Carolyn Coyne.  Bottom, immunofluorescence microscopy of 
BPIFB3-Flag-expressing U2OS cells stained for early endosomes (EEA1=green, BPIFB3-Flag=red), Golgi 
(Golgi=green, BPIFB3-Flag=red), lipid droplets (lipid droplets=green, BPIFB3-Flag=red), mitochondria 
(mitochondria=red, BPIFB3-Flag=green), or infected with ER-RFP-expressing baculovirus (ER-RFP=red, BPIFB3-
Flag=green).  DAPI-stained nuclei are shown in blue.  (B), Immunoblotting of fractions obtained from subcellular 
fractionation of U2OS cells stably expressing BPIFB3-Flag.  Blotting performed using anti-Flag antibody for BPIFB3-
Flag, anti-calnexin antibody, anti-c-Jun antibody, and anti-GAPDH antibodies.  Data are representative of at least 3 
independent experiments.   
5.2.3 Depletion of BPIFB3 results in disruption of ER architecture 
Since BPIFB3 clearly localized to the ER, we next sought to determine its role in maintenance of 
ER morphology.  To this end we performed electron microscopy on hBMECs transfected with 
either siBPIFB3 or siCON, and left untreated or treated with the vacuolar type H+-ATPase 
inhibitor Bafilomycin A (BafA) to induce cell stress and resulting alterations in ER morphology.  
Normal hBMEC ER morphology is shown in Figure 16A (left) and consists of prominent and 
regularly interspaced ER sheets.  Figure 16A right shows a moderately disrupted ER morphology 
with interrupted spatial organization of the ER sheets and increased curvature in the absence of 
BPIFB3, similar to that in cells treated with BafA (compare Figure 16A, right to Figure 16B, left).  
However, in cells treated with BafA those depleted of BPIFB3 showed an exaggerated phenotype 
of ER morphology disruption (compare Figure 16B, left to Figure 16B, center and right panels).  
Cells treated with siBPIFB3 as well as BafA showed dramatically altered spatial organization as 
compared to those treated with siCON and BafA (compare Figure 16B, left to Figure 16B center), 
as well as clear bulging of the ER sheets (i.e., a larger inner lumen space.  Compare Figure 16B, 
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left to Figure 16B, right).  These data suggest that BPIFB3 plays a role in maintaining ER structure 
and morphology. 
 
 
 
 
Figure 16. BPIFB3 plays a role in ER morphology. 
(A and B), Electron microscopy was performed on hBMECs transfected with siCON or siBPIFB3 and left untreated 
(A) or treated with 2 nm BafA for 3 hours (B).  Cells were treated by Dr. Carolyn Coyne, sections were prepared by 
the University of Pittsburgh Center for Biological Imaging EM Core, and microscopy was performed by Dr. Elizabeth 
Delorme-Axford.  Data are representative of at least 2 independent experiments.  
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5.2.4 Depletion of BPIFB3 results in disruption of ER calcium homeostasis activity 
The observation that BPIFB3 plays a role in regulation and maintenance of ER morphology led us 
to investigate the effect of depletion of BPIFB3 on ER function.  As a measure of ER function we 
chose to monitor release of ER-derived calcium stores since regulation of calcium signaling is one 
of the ER’s main functions (154).  We achieved this using the cytosolic calcium indicators Fluo-4 
and Fura-2 to directly measure cytosolic calcium levels after thapsigargin treatment-triggered 
release of calcium stores from the ER to the cytosol.  Interestingly, cytosolic calcium levels as 
measured using Fluo-4 in siBPIFB3-transfected cells fluctuated strikingly as compared to siCON-
transfected cells, suggesting a disruption of the ER’s ability to maintain its calcium levels (Figure 
17A, timepoints 0-20).  When measured using the ratiometric dye Fura-2, thapsigargin-mediated 
release of ER-derived calcium in siBPIFB3-treated cells was ~1.5-fold lower than siCON-treated 
cells, further suggesting an inability to adequately regulate ER calcium stores (Figure 17B).  
Together, these data suggest that BPIFB3 depletion-mediated loss of ER morphology corresponds 
to a loss of ER calcium homeostasis function as well. 
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Figure 17. BPIFB3 affects maintenance of ER-derived calcium stores. 
(A), Fluctuations in cytosolic calcium levels prior to thapsigargin-mediated release of ER-derived calcium stores.  
Graphs depict fluorescence intensity of 30 regions of interest (ROIs) over time chosen from images of hBMECs 
transfected with siBPIFB3 or siCON and loaded with Fluo-4, prior to treatment with 1µM thapsigargin.  (B), 
Thapsigargin (1µM)-mediated calcium release in hBMECs transfected with siBPIFB3 or siCON and loaded with the 
ratiometric dye Fura-2.  Data in (A) are representative of at least 3 independent experiments and data in (B) are from 
at least 3 independent experiments and are shown as mean±SEM for 30 ROIs.    
5.2.5 Depletion of BPIFB3 results in a dramatic enhancement of VSV syncytia formation 
and alterations in vesicular trafficking 
Upon investigating the effect of BPIFB3 silencing on the infection of viruses other than CVB, we 
observed the striking effect that depletion of BPIFB3 in hBMECs led to a dramatic increase in 
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syncytia formation in VSV-infected cells (Figure 18A).  However, the increase in syncytia 
formation was not merely a reflection of increased VSV titers, since plaque assays of VSV 
propagated in hBMECs transfected with siCON or siBPIFB3 actually showed a moderate (!1.5-
fold) decrease in VSV titers in the absence of BPIFB3 (Figure 18B).  It is important to note that 
the VSV glycoprotein (VSV-G) can act as a fusogenic protein, and that its fusogenic properties 
are highly dependent on pH (250).  However, data generated by others in the lab showed that both 
extracellular and cytosolic pH remained unchanged in the absence of BPIFB3 (data not shown), 
suggesting that the mechanism of VSV-mediated-syncytia enhancement in the absence of BPIFB3 
is independent of a global change in cellular pH.  For further exploration into the mechanism of 
syncytia enhancement we performed EM on hBMECs transfected with siCON or siBPIFB3 and 
left untreated or treated with BafA to ‘freeze’ progression of the endosomal pathway (251), in 
order to look for alterations in vesicular trafficking.  Examination of the resulting intracellular 
vesicular environment showed an enhancement of the size and number of vesicles (Figure 18C).  
Immunofluorescence microscopy performed by others in the lab revealed the identity of these 
vesicles as early endosomes and lysosomes (data not shown).  Together, these data suggest that 
depletion of BPIFB3 results in significant alterations in intracellular vesicular trafficking, and that 
these alterations could lead to incorrect VSV trafficking and syncytia formation. 
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Figure 18. BPIFB3 regulates intracellular vesicular trafficking, affecting VSV syncytia formation. 
(A), VSV-GFP-induced syncytia in hBMECs transfected with siCON or siBPIFB3 and infected with VSV-GFP ~16 
hrs.  VSV-GFP is shown in green and DAPI-stained nuclei are shown in blue.  (B), Titers (pfu/mL) of VSV-GFP 
propagated for ~16 hrs on hBMECs transfected with siBPIFB3 or siCON.  (C), Electron microscopy was performed 
on hBMECs transfected with siCON or siBPIFB3 and treated with 2 nm BafA for 3 hours.  Cells were treated by Dr. 
Carolyn Coyne, sections prepared by the University of Pittsburgh Center for Biological Imaging EM Core, and 
microscopy was performed by Dr. Elizabeth Delorme-Axford.  Data in (A) are representative of at least 3 independent 
experiments, and data in (C) are representative of at least 2 different experiments.  Data in (B) are from at least 3 
independent experiments, and are presented as mean ± standard deviation. 
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5.2.6 BPIFB3 plays a role in infection of diverse viruses 
As discussed above, the host cell ER is co-opted by a variety of different viruses for completion 
of their life cycles in a variety of different ways.  In order to further delineate the role of BPIFB3 
in CVB infection we tested the effect of BPIFB3 depletion on the infection of two other 
enteroviruses that also likely use ER-derived membranes for their replication.  As expected, 
BPIFB3 depletion resulted in significant enhancement of both PV and enterovirus 71 (EV71) 
infection (~1.5-2-fold) (Figure 19A).  To examine this point even further we tested the effect of 
BPIFB3 depletion on the infection of VSV (a negative-sense RNA virus) and VV (a DNA virus).  
Indeed, depletion of BPIFB3 affected infection of these viruses, but in contrast to its effect on 
enteroviruses, it actually decreased the infection of VSV and VV by more than 50% (Figure 19B).  
This outcome likely reflects the differential use of host-derived membranes in the life cycles of 
diverse viruses, but suggests that BPIFB3 is crucial for this process. 
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Figure 19.  BPIFB3 plays a role in infection of diverse viruses. 
(A), Enhanced CVB, PV, and EV71 infection in hBMECs transfected with siBPIFB3 compared to siCON, as assessed 
by immunofluorescence microscopy at 16 hrs post-infection.  VP1 staining is shown in green and DAPI-stained nuclei 
are shown in blue.  (B), Decreased VSV-GFP and VV-YFP infection in hBMECs transfected with siBPIFB3 compared 
to siCON, as assessed by qPCR 16 hrs post-infection. All data are from at least 3 independent experiments and are 
presented as mean ± standard deviation (*p<0.05). 
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5.3 DISCUSSION 
Here we report on the characterization of BPIFB3 (LPLUNC3), a previously un-characterized 
protein identified as a regulator of enterovirus replication by unbiased high-throughput screening.  
The BPI/LBP family of proteins contains members with lipid-binding and antimicrobial properties 
(191).  The PLUNC subfamily (including BPIFB3) consists of largely uncharacterized BPI 
homologs that seem to retain the BPI/LBP family’s lipid-binding properties, but not the ability to 
neutralize or kill bacteria (202).  Since BPIFB3 contains a lipid-binding region suggesting it could 
play a role in regulating lipids/membranes required for viral replication, and its function has not 
been clearly reported, we found it to be an interesting protein for follow up. 
 We showed that BPIFB3 is localized to the ER, and that depletion of BPIFB3 resulted in a 
disruption of ER morphology and calcium homeostasis.  These results suggest that BPIFB3 is a 
novel component of the ER, and that it plays a role in maintenance of ER morphology and 
structure.  The enhancement of this phenotype in the presence of ER stress induced by BafA 
treatment further confirms a role for BPIFB3 in maintenance of ER structure and morphology, as 
this would suggest an inability of the ER to counter stress-induced alterations in the absence of 
BPIFB3.  Because of the presence of two lipid binding regions in its structure, it is possible that 
BPIFB3 is an integral membrane component of the ER, inserting directly into the membrane via 
its lipid binding regions.  In this capacity BPIFB3 could play a role as an adaptor or regulator 
(either directly or indirectly) of important ER membrane-bound proteins known to play a role in 
ER morphology.  Interestingly, EM pictures of the ER in the absence of BPIFB3 showed a 
disruption of flat, perinuclear, closely spaced and stacked ER sheets, resulting in a less spatially 
organized series of ER sheets that showed more curvature, and therefore seemed tubular in nature.  
This phenotype was exaggerated in the presence of BafA-induced ER stress, with evidence of 
 86 
thickening of the ER sheets.  ER morphology is largely maintained by a group of ER-membrane 
proteins, with membrane curvature induced by the reticulon and DP1/Yop1p proteins (163-165).  
In contrast, the flatness and intralumenal spacing of stacked perinuclear ER sheets is maintained 
by the Climp63, p180, and kinectin proteins (164, 166).  The function of these ER morphology-
generating proteins rely on their insertion into the ER membrane, and they could therefore interact 
with ER-membrane localized BPIFB3.  Since depletion of BPIFB3 generated a more curved ER 
membrane phenotype, BPIFB3 could have a positive regulatory role on p180 or kinectin via direct 
protein-protein interaction, since these two proteins have been shown to maintain flatness of 
perinuclear ER sheets.  Conversely, BPIFB3 could have a negative regulatory role via direct 
interaction with the reticulon and/or DP1/Yop1p proteins, since they have direct roles in generating 
and maintaining ER curvature.  An increase in ER membrane curvature could, in turn, affect the 
function of many other ER membrane-bound proteins.  For example, the conformation of ER 
membrane-bound calcium release receptors responsible for calcium homeostasis such as IP3 could 
be disrupted and therefore function aberrantly due to the unusual amount of curvature in the 
membrane, accounting for the loss of calcium homeostasis seen in BPIFB3-depleted cells. 
 Also among the candidates for interaction with BPIFB3 in the ER membrane are 
phosphatidylinositol kinases (PIK).  They are responsible for phosphorylation of PIs, which are 
important components of cellular membranes.  The distribution of PI and its various 
phosphorylation states (or PIPs), along with the group of membrane-bound proteins associated 
with a particular organelle’s “lipid signature” essentially determines the identity and function of 
an organelle (252-254).  Disruption of the function of PIKs and therefore distribution of PI and its 
various phosphorylation states can have many consequences for the cell.  For example, PI 
composition of membranes can affect the size, shape and rigidity of the ER.  In this scenario, 
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BPIFB3 interaction and regulation of an ER-bound PIK could impact the morphology of the ER 
simply by triggering over or under-production of a key PI required for flattened membrane 
morphology.  Importantly, IP3, a metabolite of the phosphorylated membrane PI PI(4,5)P2,  
regulates calcium homeostasis of the ER by binding to IP3 receptors on the smooth ER, initiating 
calcium release into the cytosol (255, 256).  This could provide an explanation for the disruption 
of calcium homeostasis seen with BPIFB3 depletion since overproduction of this phosphorylated 
form of PI due to increased PIK activity could provide abnormally high levels of IP3, therefore 
trapping the IP3 receptor in an “open” conformation and dis-regulating calcium homeostasis.        
The interesting finding that depletion of BPIFB3 resulted in greatly enhanced VSV-
mediated syncytia formation independent of a titer increase was unexpected.  The process of VSV-
mediated syncytia formation has been previously recognized but remains poorly characterized 
(257).  VSV contains a highly fusogenic surface glycoprotein used for entry (VSV-G), and its 
fusogenic properties are reported to be pH-dependent and thus only activated once in the vesicular 
compartment containing the correct pH (250).  Since others in the lab found that both extracellular 
and cytosolic pH were unchanged upon depletion of BPIFB3, we reasoned that the increased 
fusogenecity of VSV could be due to an increased availability of low pH-containing vesicles.  
Indeed, EM showed an increase in size and number of vesicular structures, and 
immunofluorescence microscopy done by others in the lab showed an increase in size and number 
of early endosomes and lysosomes in BPIFB3-depleted cells.  This would provide the appropriate 
environment for enhanced fusion and could explain the increase in VSV-mediated syncytia.  
Recent work has shown that significant contact between the ER and the endosomal/lysosomal 
system occurs to facilitate interactions between membrane components of the ER and 
endosomes/lysosomes (159, 258, 259), which would provide an explanation for how BPIFB3, an 
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ER-localized protein, could affect the endosomal/lysosomal pathway.  This interaction is known 
to occur along the smooth, peripheral ER, and since depletion of BPIFB3 results in a higher level 
of curvature mimicking the morphology of the smooth ER, a higher level of contact between ER 
and endosomes in the absence of BPIFB3 is possible.  Maturation of endosomes requires “PI 
conversion” to progressively higher phosphorylated species of PI in the endosomal membrane, a 
process requiring PIK (168, 169, 171, 177, 178).  Thus, a higher level of ER-endosome contact, or 
altered levels of PIK activity in the absence of BPIFB3 could provide a larger and/or more 
available pool of resources (i.e., PIK and/or highly phosphorylated PIs) for enhanced maturation 
of endosomes to the larger and lower pH-containing species of mature endosomes/lysosomes.  This 
would, in turn, provide a larger reservoir of low-pH containing mature endosomes/lysosomes for 
increased fusogenic activity of VSV-G.  Conversely, data have shown that inhibition of PI 
conversion leads to a highly vacuolated phenotype and enlarged endosomes (179-181), raising the 
notion that altered levels of PIK activity in the absence of BPIFB3 could also provide a smaller or 
less available pool of PIK or PIP, leading to the same outcome of enhanced size/number of 
endosomes/lysosomes and an enhanced reservoir of low-pH containing mature 
endosomes/lysosomes for increased fusogenic activity of VSV-G.   
Enteroviruses utilize components derived from the ER and secretory system, such as the 
ER-Golgi intermediate compartment (ERGIC) and Golgi to form replication complexes (19, 260, 
261).  Disruption of ER morphology upon depletion of BPIFB3 would likely lead to 
dysfunction/disassembly of components of the secretory pathway, therefore providing a source of 
material for increased replication complex assembly.  This could explain the increase in 
enterovirus infection observed upon BPIFB3 depletion.  Alternatively, the increase in membrane 
curvature evident in the absence of BPIFB3 could provide increased surface area for formation of 
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secondary viral replication complexes.  Secondary viral replication centers were shown to form at 
ER exit sites, which exist in areas of high membrane curvature (19, 162).  This idea is bolstered 
by the finding that PV utilizes the host protein ARF1 to recruit other host proteins responsible for 
increasing the membrane curvature at areas of viral replication (20, 21), showing that enteroviruses 
favor highly curved membranes for their replication.  The possible role for BPIFB3 in regulation 
of PI kinase activity discussed above could provide another possible explanation for enhancement 
of enteroviral infection in the absence of BPIFB3.  Enteroviruses have been shown to recruit and 
require PI4KIIIβ for their replication, therefore a scenario in which BPIFB3 depletion enhances 
the availability or activity of this kinase would increase enteroviral replication.    
  Depletion of BPIFB3 resulted in a marked decrease in both VV and VSV infection.  
Different viruses have different requirements of intracellular membranes for their replication.  In 
the case of VV, cytoplasmic replication is organized into foci that are surrounded by rough ER 
(247-249).  The finding that BPIFB3 depletion led to disruption of closely stacked ER sheets and 
higher curvature in the ER membrane could account for this, since the absence of traditional rough 
ER morphology could cause problems with VV recruitment of membranes for viral replication.  
As for VSV, VSV-G trafficking through the Golgi is vital for completion of its lifecycle and release 
of new infectious virions (262, 263).  The increase in endosomal/lysosomal vesicular 
compartments in the absence of BPIFB3 could make VSV-G trafficking and hence assembly of 
new viral particles difficult due to the availability of low pH-containing endosomes/lysosomes for 
fusion, which are known to cycle from the Golgi compartment as well as the endocytic 
compartment (168).  This would shuttle the VSV-G away from the secretory system and to the 
endosomal/lysosomal system, sequestering it from the plasma membrane where VSV requires it 
for assembly and budding.        
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Overall, we have made significant progress towards the characterization of a novel 
regulator of ER morphology identified by high throughput RNAi screening.  We have provided 
evidence that BPIFB3 plays a significant role in the replication of a diverse set of viruses, the 
differing effect of its depletion on infection highlighting the known differences between their 
replication cycles.  Importantly, this work has also shown that BPIFB3 plays a role in regulation 
of the endosomal/lysosomal pathway, likely indirectly through its effects on the ER and the known 
interaction between the endosomal/lysosomal pathway and the ER.  Important work is ongoing in 
the lab to determine the exact mechanism(s) by which BPIFB3 achieves these effects. 
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6.0  FINAL DISCUSSION 
Understanding the interactions between a virus and its host cell is critical in order to improve upon 
existing treatments and vaccines.  Towards the goal of better understanding this interaction, we 
previously conducted a high-throughput RNAi screen for host cell factors involved in enterovirus 
infection (205).  Whereas similar screens have been reported this screen was particularly 
innovative since it was performed in a polarized cell type, more closely resembling the conditions 
of physiological infection.  Of the ~5,000 genes screened for their effect on enterovirus infection, 
117 ‘hits’ were identified whose depletion affected enterovirus infection.  Of the 117 hits, 46 genes 
were found whose depletion led to a decrease in both CVB and PV infection and were considered 
to be broadly pro-viral and 17 genes were found whose depletion led to an increase in both CVB 
and PV infection and were considered to be broadly anti-viral.  Of these hits, we chose two 
different genes for follow up: Gp78 and BPIFB3.   
The multitude of interesting targets yielded by the RNAi screen has opened up possibilities 
for many different future directions in identifying previously uncharacterized interactions between 
the host cell and virus.  Indeed, some of these ‘hits’ are being pursued in the lab, and many more 
remain to be investigated.  The knowledge regarding host-virus interactions to be gained from 
pursuit of these targets will provide critical information on previously unrecognized interactions 
that could be exploited for the purpose of novel treatments or vaccines. 
Depletion of Gp78 resulted in a decrease of enterovirus infection, and we found it to be an 
interesting target due to its E3 ligase activity and its localization at the MAM in close proximity 
to the MAVS-containing innate immune signaling synapse.  We went on to further characterize 
the mechanism of siGp78-mediated repression of enteroviral replication and found that its 
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depletion resulted in decreased infection of other RNA viruses as well.   This effect was later found 
to be due to the ability of Gp78 to repress type I interferon signaling.  Gp78 achieves this effect 
by two mechanisms, causing degradation of the MAM-localized RLR signaling adaptor protein 
MAVS, and binding directly to MAVS, preventing critical upstream and downstream interaction.  
Therefore, Gp78 is not pro-viral in the traditional sense (i.e., the virus does not use it directly for 
completion of its life cycle), but rather the host cell uses it as a mechanism to prevent excessive 
inflammation by downregulating expression and repressing activity of a key innate immune 
mediator.  In conclusion, pursuit of the screen ‘hit’ Gp78 as a potential regulator of virus infection 
resulted in successful description of a novel function for Gp78 in regulation of type I interferon 
signaling. 
Although the role of Gp78 in virus infection has been described in chapter 4 of this 
dissertation, there are many remaining questions for follow-up studies to address.  For example, it 
would be interesting to expand upon the virus panel used, testing the effect of Gp78 depletion on 
infection of a few more viruses known to signal through MAVS, as well as a few that do not signal 
through MAVS.  A further characterization of the interaction between MAVS and Gp78 would 
also be informative.  Our data show that Gp78 expression is not induced upon SeV, purified IFN, 
or poly(I:C) treatment, and that the expression of ISG56 increased slightly upon depletion of Gp78 
in the absence of stimulation.  Both of these observations suggest that Gp78 plays a housekeeping 
role in MAVS downregulation, preventing excessive inflammation.  This is crucial in preventing 
autoimmunity or cellular/tissue damage due to the onslaught of inflammation in the absence of an 
invading threat.  However, it is possible that the strength or amount of interaction between MAVS 
and Gp78 could increase in the presence of type I interferon signaling, and this could be tested by 
performing coimmunoprecipitation studies in the presence and absence of SeV, purified IFN, or 
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poly(I:C).  If the interaction is indeed increased in the presence of stimulation it would suggest 
that, whereas Gp78 expression itself is not inducible, the interaction between Gp78 and MAVS is 
at least partly inducible.  Although this would not negate the possibility of a housekeeping role for 
Gp78 in MAVS regulation, it would further explain how Gp78 could prevent excessive 
inflammation with a negative feedback system.   
Additionally, mapping of the regions of MAVS required for interaction with Gp78 would 
further clarify which MAVS interactions are disrupted by its interaction with Gp78.  Our data show 
that Gp78 interacts with both the C- and N-terminal fragments of MAVS, but only the N-terminus 
is required for Gp78-mediated degradation.  It is likely that an independent interaction is necessary 
to achieve each mechanism of downregulation (i.e., degradation and interaction causing disruption 
of critical signaling interactions), and further mapping MAVS interaction sites may lead to 
important information about the interaction.  For example, if the CARD of MAVS contains the 
area of ubiquitination and therefore the first area of interaction mediating 
ubiquitination/degradation, then the C-terminal fragment must contain the residues responsible for 
the interaction causing signaling disruption.  If this is the case, then Gp78-MAVS interaction must 
disrupt the ability of MAVS to bind to the downstream signaling partner TRAF3, since this is the 
only known binding region in the C-terminus corresponding to up/downstream MAVS signaling 
partners.  Of course, it is possible that multiple interactions between Gp78 and MAVS occur and 
cause blocking of more than one critical up/downstream signaling interaction.  Mapping of the 
MAVS sites of interaction would further clarify these questions.   
From the data presented, it is not clear whether the interaction between Gp78 and MAVS 
is a direct interaction or an indirect interaction in a multi-protein complex.  Direct interaction could 
be tested using recombinant MAVS and Gp78 in a cell-free system.  If the interaction is not direct, 
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identification of any additional interacting partners could be achieved by performing mass 
spectrometry on the complex pulled down in a coimmunoprecipitation study. 
Interestingly, our collaborator Dr. Ivan Nabi’s group is currently searching for the motif 
within Gp78 responsible for tethering it to the MAM.  Unpublished data from another group has 
shown that Gp78 leaves the MAM in the context of viral infection, which is consistent with our 
findings that it negatively regulates MAVS in a housekeeping manner.  Results from both of these 
studies would provide valuable insight to the function of Gp78 in the context of viral infection. 
Depletion of BPIFB3 resulted in an enhancement of enterovirus infection, and we chose to 
pursue this target due to its lack of characterization, and reports of lipid-binding properties given 
its sequence and structural similarities to BPI.  As we went on to further characterize its role in 
enterovirus infection, we surprisingly found that its depletion led to a decrease of infection of VSV 
and VV, as well as significant enhancement of VSV-mediated syncytia.  Examination of its 
subcellular localization revealed a largely ER-centered localization pattern, and EM of cells 
lacking BPIFB3 showed disrupted ER architecture, a phenomenon that was greatly enhanced under 
conditions of ER stress, and disruption of calcium homeostasis, along with enhanced numbers and 
size of endosomes/lysosomes.  Taken together, these observations and data suggested that the 
previously uncharacterized BPIFB3 is a novel component of the ER with a role in maintenance of 
ER architecture and the endosomal/lysosomal pathway, perhaps by affecting ER morphology-
inducing proteins or lipid organization/content.  This in turn affects the replication of any virus 
that utilizes intracellular membranes in their replication.  These findings are quite surprising, given 
that other members of the PLUNC subfamily of proteins, along with members of the BPI/LBP 
family, have been reported to function as secreted antimicrobial peptides (197-203).  This 
highlights the need for further work in characterization of this family of proteins. 
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Work described in Chapter 5 of this dissertation represents a major stride toward 
characterization of BPIFB3.  However, there are many remaining questions for future study and 
further characterization, some of which are being pursued in the lab currently.  The most important 
question to address is regarding the mechanism for maintenance of ER morphology.  How does 
BPIFB3 maintain, or help to maintain, correct ER architecture?  We have speculated that BPIFB3 
could insert into the ER membrane via its lipid binding domains and therefore interact with 
proteins that are required for maintenance of ER morphology, such as the reticulons, DP1 proteins, 
Climp63, kinectin, or p180.  As discussed earlier, this would have implications for the replication 
of ER-requiring viruses, endosome/lysosome trafficking, as well as calcium homeostasis.  The 
ability of BPIFB3 to insert into the membrane could be tested by mutational analysis of the lipid 
binding regions followed by confocal microscopy-based localization studies.  The interaction 
between BPIFB3 and proteins involved in ER morphology maintenance could be tested using a 
protein interaction assay, such as yeast-two hybrid using BPIFB3 as bait.  Identifying any 
interacting partners of BPIFB3 that are involved in ER morphology induction/maintenance would 
be helpful in moving toward finding the mechanism of BPIFB3-induced ER morphology 
maintenance.     
We have also speculated that BPIFB3 could alter ER morphology by altering the membrane 
lipid content via interactions with PIK in the ER membrane.  As discussed earlier, this would have 
implications in the replication of PIK-requiring viruses, endosome/lysosome trafficking, as well 
as calcium homeostasis.  Interaction between BPIFB3 and various PIKs could be tested by yeast-
two hybrid as well, again using the BPIFB3 as bait.  Measurement of the level of PIPs, as well as 
overall lipid content of the cells in the absence of BPIFB3 could also be informative in 
investigating this hypothesis.     
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Based on the results of our studies, we have hypothesized that depletion of BPIFB3 could 
affect viral replication as a result of ER morphology disruption.  This is presently being tested by 
performing EM on BPIFB3-depleted cells that have been infected with the various viruses used in 
the study.  The imaging results will provide insight into the formation of ER or secretory system-
derived viral replication centers in the absence of BPIFB3, as well as the architecture of the VSV-
induced syncytia present in BPIFB3-depleted cells. 
BPIFB3 is a member of the PLUNC subfamily of proteins, many members of which have 
yet to be fully characterized.  Therefore, the testing of other family members represents an 
interesting area for follow-up that could give good insight into the function of BPIFB3.  This work 
is also ongoing in the lab. 
In conclusion, the results obtained from the studies in this dissertation have provided a 
significant amount of new information for the field of virus-host interaction.  We have contributed 
new and important insight into regulation of the host innate immune response to viruses, 
identifying Gp78 as a novel regulator of the immune adaptor MAVS.  We have also taken strides 
towards identifying the function of a novel component of the ER, which seems to play an important 
role in regulation of ER morphology and endo/lysosomal trafficking and therefore in the infection 
of diverse viruses.  Interestingly, both of these regulators of viral infection function from the ER 
(Figure 20).  Although some important questions remain unanswered, these studies have 
contributed to and underscored the need to continue work on virus-host interaction.  
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Figure 20.  RNAi HTS identifies two regulators of viral infection that regulate from the ER. 
This dissertation has described two regulators of viral infection, both of which regulate from the ER.  Gp78 is localized 
to the peripheral ER in close association with mitochondria, and interacts with MAVS to downregulate MAVS-
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induced antiviral signaling.  BPIFB3 is localized to the ER and plays a role in maintenance of correct ER morphology, 
thereby affecting replication of any viruses that utilize the ER for replication. 
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7.0  PUBLIC HEALTH SIGNIFICANCE 
To develop highly effective and targeted therapeutics for viral infections it is crucial to gain a more 
complete understanding of the complex interaction between the virus and its host cells.  The host 
cell factors that are co-opted by the virus for its own use, as well as host strategies to contain viral 
infection and the resulting viral evasion techniques that evolve may all contain possible therapeutic 
targets buried within them.  A highly efficient way of analyzing this interaction is using RNAi 
screens within relevant biological systems.  This dissertation is an example of two novel and 
important virus-host interactions that were identified and characterized as a result of an RNAi 
screen.  This work has public health significance because these findings will further our 
understanding of the virus-host interaction, which will, in turn, lead to the ability to better develop 
antiviral therapeutics. 
 In Chapter 4 of this dissertation we describe a novel modulator of antiviral immunity, 
providing further characterization of the innate antiviral immune response.  The innate antiviral 
immune response is an important host-virus interaction to understand due to the role of host 
immunity in vaccine effectiveness.  The more we know about the physiological events following 
a natural infection, the more we can try to modulate it for the purpose of vaccination or treatment.  
Finally, in Chapter 5 of this dissertation we describe a novel component/regulator of ER 
morphology and function and show its importance in the replication of a diverse set of viruses.  
The process of viral co-opting of host cell membranes is just beginning to be appreciated as a 
highly important host-virus interaction.  Any step in which a virus is at the mercy of the host cell 
for acquisition of components crucial to complete its life cycle is a step that could potentially be 
used for development of anti-viral therapeutics.    
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APPENDIX A:  ABBREVIATIONS USED 
5'-ppp:  5' triphosphate 
AIP4:  Atrophin-I-interacting protein 4 
AMF:  Autocrine motility factor 
AMFR:  Autocrine motility factor receptor 
AMPK:  Adenosine 5' monophosphate-activated protein kinase 
ANOVA:  Analysis of variance 
ATG5:  Autophagy protein 5 
ATP:  Adenosine triphosphate 
BafA:  Bafilomycin A 
BPI:  Bactericidal/permeability increasing  
BPIFB3:  BPI fold containing family B, member 3 
Ca2+:  Calcium 
CAR:  Coxsackievirus and adenovirus receptor 
CARD:  Caspase activation and recruitment domain 
CARDIF:  CARD adapter inducing interferon-beta 
CCCP:  Carbonyl cyanide m-chlorophenylhydrazone 
CD:  Cluster of differentiation 
cDNA:  Complementary DNA 
CETP:  Cholesterylester transfer protein  
Cig5:  Cytomegalovirus-induced gene 5  
COX5B:  Cytochrome C oxidase 5B 
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CT:  C terminus 
CUE:  Coupling of ubiquitin to ER degradation 
CVB:  Coxsackievirus B 
DAF:  Decay accelerating factor 
DAPI:  4′,6-diamidino-2-phenylindole  
DEAD:  Asparagine-Glutamine-Alanine-Asparagine 
DMEM-H:  Dulbecco's modified eagle medium high glucose 
DNA:  Deoxyribonucleic acid 
dsRNA:  Double stranded RNA 
∆ψM:  Mitochondrial membrane potential 
EDTA:  Ethylenediaminetetraacetic acid 
EGFP:  Enhanced green fluorescent protein 
EM:  Electron microscopy 
EMCV:  Encephalomyocarditis virus  
ER:  Endoplasmic reticulum 
ERAD:  ER-associated degradation  
EV71:  Enterovirus 71 
FAK:  Focal adhesion kinase 
FASN:  Fatty acid synthase 
FBS:  Fetal bovine serum 
G2BR:  G2 binding region 
GAPDH:  Glyceraldehyde 3-phosphate dehydrogenase 
gC1qR:  Receptor for globular head domain of complement component C1q 
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GFP:  Green fluorescent protein 
Gp78:  Glycoprotein 78 
GTP: Guanosine triphosphate 
HAU:  Hemagglutination units 
HBMEC:  Human brain microvascular endothelial cells 
HCl:  Hydrochloric acid 
HCV:  Hepatitis C virus 
HEK:  Human embryonic kidney 
hGp78:  Human Gp78 
HMW:  High molecular weight 
hrs:  Hours 
Hsp:  Heat shock protein 
IB:  Immunoblot 
IFIT3:  Interferon-induced protein with tetratricopeptide repeats 3  
IFN:  Interferon 
IgM:  Immunoglobulin M 
IKKe: Inhibitor-κB kinase ε 
IP:  Immunoprecipitation 
IPS-1:  Interferon-beta promoter stimulator 1 
IRES:  Internal ribosome entry site 
IRF:  Interferon regulatory factor 
ISG:  Interferon-stimulated gene 
IκB:  NF-κB inhibitor 
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K:  Lysine 
kDa:  Kilodalton 
LBP:  LPS binding protein 
LGP2:  Laboratory of genetics and physiology gene 2 
LPLUNC:  Long PLUNC 
LPS:  Lipopolysaccharide 
LRR:  Leucine-rich-repeat 
M:  Molar 
MAM:  Mitochondria-associated ER membrane 
MAVS:  Mitochondrial antiviral signaling 
MDA5:  Melanoma differentiation-associated protein 5 
MEF:  Mouse embryonic fibroblast 
MFN:  Mitofusin 
µg:  Microgram 
mg:  Milligram 
mGp78:  Mouse Gp78 
µL:  Microliter 
mL:  Milliliter 
µM:  Micromolar 
mM:  Millimolar 
mRNA:  Messenger RNA 
MyD88:  Myeloid differentiation primary response gene 88 
NaCl:  Sodium chloride 
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NBD:  Nucleotide-binding domain 
Ndfip1:  Nedd4 family interacting protein 1 
Nedd4:  Neural precursor cell expressed, developmentally down-regulated 4 
NF-κB:  Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
ng:  Nanogram 
NLRX1:  Nucleotide-binding domain-and leucine-rich-repeat-containing family member 1 
nM:  Nanomolar 
NP-40:  Nonyl phenoxypolyethoxylethanol 
NT:  N terminus 
PBS:  Phophate-buffered saline 
PCBP:  Poly(rC) binding protein  
PCR:  Polymerase chain reaction 
pDCs:  Plasmacytoid dendritic cells 
Pfu:  Plaque forming units 
PI4-kinase:  Phosphatidylinositol 4-kinase 
PLK1:  Polo-like kinase 1 
PLTP:  Phospholipid transfer protein  
PLUNC:  Palate, lung and nasal epithelium clone 
Poly-A:  Poly-adenylate 
Poly(I:C):  Polyinosinic:polycytidylic acid 
PSMA7:  Proteasome subunit alpha type-7 
PV:  poliovirus 
Rac:  Ras-related C3 botulinum toxin substrate 
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RDRP:  RNA-dependent RNA polymerase 
Rf:  RING finger 
RFP:  Red fluorescent protein 
RIG-I:  Retinoic acid-inducible gene I 
RING:  Really interesting new gene 
RIPA:  Radioimmunoprecipitation assay 
RLR:  RIG-I-like receptor 
RNA:  Ribonucleic acid 
RNAi:  RNA interference 
ROI:  Region of interest 
ROS:  Reactive oxygen species 
RT-qPCR:  Reverse transcriptase quantitative polymerase chain reaction 
RT:  Room temperature 
SEM:  Standard error of the mean 
SeV:  Sendai virus 
Smurf1:  SMAD specific E3 ubiquitin protein ligase 1 
SPLUNC:  Short PLUNC 
ssRNA:  Single stranded RNA 
STING:  Stimulator of interferon genes 
TANK:  TRAF family member-associated NF-κB activator  
TBK1:  TANK binding kinase 1 
Thap:  Thapsigargin 
TLR:  Toll like receptor 
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TNF:  Tumor necrosis factor 
Tom70:  Translocase of outer membrane 70  
TRADD:  TNFR1-associated death domain protein 
TRAF:  TNF receptor associated factor   
TRIF:  TIR-domain-containing adapter-inducing interferon-β 
TRIM25:  Tripartite motif containing 25 
TRIS:  Trisaminomethane 
TSPAN6: Tetraspanin protein 6 
Tyr:  Tyrosine 
U:  Units 
VCP:  Valosin-containing protein 
VIM:  VCP interacting motif 
VISA:  Virus-induced signaling adapter 
VP1:  Viral protein 1 
VSV:  Vesicular stomatitis virus 
VV:  Vaccinia virus 
WT:  Wild type 
YFP:  Yellow fluorescent protein 
Δ:  Deleted 
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APPENDIX B:  CHOOSING THE TARGETS 
As mentioned previously, the RNAi screen revealed a number of potential regulators of enterovirus 
infection.  Therefore, it is important to describe our method for choosing the ‘hits’ Gp78 and 
BPIFB3 for follow-up study.  
After assessing any reported functions for each screen hit we chose about 25 that we 
thought could be involved in innate immunity, including Gp78.  We felt Gp78 may be involved in 
innate immunity due to its reported function as an E3 ubiquitin ligase (E3 ubiquitin ligases have 
been reported to regulate various aspects of innate immunity).  We therefore screened the 25 hits 
we suspected of being involved in innate immunity in a luciferase reporter-based IFN-β promoter 
assay (data available upon request).  Expression of Gp78 caused the most prominent reduction in 
IFN-β activity, so we chose to pursue the function of Gp78 in the innate antiviral immune response. 
Our interest in BPIFB3 originated simply because its depletion resulted in the greatest 
increase in enterovirus infection, leading us to speculate that it could be a component of the innate 
antiviral response as well.  Our interest was increased when we realized that BPIFB3 was not 
functionally characterized, but it was likely a lipid-binding protein (many lipid-binding proteins 
are known to be involved in innate antiviral immunity).  We therefore chose to pursue 
characterization of the role of BPIFB3 in virus infection.  
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